

**This item is the archived peer-reviewed author-version of:**

Spectroscopic investigations, DFT calculations, molecular docking and MD simulations of 3-[(4-Carboxyphenyl) carbamoyl]-4-hydroxy-2-oxo-1, 2-dihydroxy quinoline-6-carboxylic acid

**Reference:**

Ranjith P.K., Ignatious Angel, Panicker C. Yohannan, Sureshkumar B., Armakovic Stevan, Armakovic Sanja J., Van Alsenoy Christian, Anto P.L.. - Spectroscopic investigations, DFT calculations, molecular docking and MD simulations of 3-[(4-Carboxyphenyl) carbamoyl]-4-hydroxy-2-oxo-1, 2-dihydroxy quinoline-6-carboxylic acid  
Journal of molecular structure - ISSN 1872-8014 - 1264(2022), 133315  
Full text (Publisher's DOI): <https://doi.org/10.1016/J.MOLSTRUC.2022.133315>  
To cite this reference: <https://hdl.handle.net/10067/1890710151162165141>

1 Spectroscopic investigations, DFT calculations, molecular docking and MD  
2 simulations of 3-[(4-Carboxyphenyl) carbamoyl]-4-hydroxy-2-oxo-1, 2-dihydroxy  
3 quinoline-6-carboxylic acid.

4

5 P. K. Ranjith<sup>a,b</sup>, Angel Ignatious<sup>c</sup>, C. Yohannan Panicker<sup>d</sup>, B. Sureshkumar<sup>e</sup>, Stevan  
6 Armakovic<sup>f</sup>, Sanja J. Armakovic<sup>g</sup>, C. Van Alsenoy<sup>h</sup>, P. L. Anto<sup>a,c\*</sup>

7

8 <sup>a</sup> Department of Physics, Christ College (Autonomous), Irinjalakuda, Thrissur,  
9 Kerala, India

10 <sup>b</sup> Department of Physics, MPMMSN Trusts College, Shoranur, Palakkad, Kerala,  
11 India

12 <sup>c</sup> Department of Physics, St. Joseph's College (Autonomous), Irinjalakuda,  
13 Thrissur, Kerala, India

14 <sup>d</sup> Thushara, Neethinagar-64, Kollam, Kerala, India.

15 <sup>e</sup> Department of Chemistry, Sree Narayana College, Kollam, Kerala, India

16 <sup>f</sup> University of Novi Sad, Faculty of Sciences, Department of Physics, Trg D.  
17 Obradovica 4, 21000 Novi Sad, Serbia

18 <sup>g</sup> University of Novi Sad, Faculty of Sciences, Department of Chemistry,  
19 Biochemistry and Environmental Protection, Trg D. Obradovica 3, 21000 Novi  
20 Sad, Serbia

21 <sup>h</sup> Department of Chemistry, University of Antwerp, Groenenborgerlaan 171, B-  
22 2020, Antwerp, Belgium

23

24 \* Corresponding author: email address: [antoponnore367@gmail.com](mailto:antoponnore367@gmail.com) (P. L. Anto)

25

## 26 **Abstract**

27 In this article, the synthesis, experimental vibrational spectroscopic analysis (FT-IR  
28 and FT-Raman) and theoretical calculations of Quiniline derivative 3-[(4-  
29 Carboxyphenyl) carbamoyl]-4-hydroxy-2-oxo-1, 2-dihydroxy quinoline-6-  
30 carboxylic acid (CPCHODQ6C) were studied. The investigation of the IR and  
31 Raman spectra of the molecule under study, supported by DFT calculations, has  
32 afforded the opportunity to characterize explicitly the main vibrational bands for the  
33 title molecule, which is primarily used as anti-malaria compound. Computational  
34 calculations were done using B3LYP/6-31G(d) basis set. Vibrational assignments of

35 wavenumbers were performed on the basis of potential energy distribution. The  
36 downshift from the DFT value and the splitting of N-H stretching mode indicates the  
37 weakening of the N-H bond. Donor acceptor interactions were evaluated using NBO  
38 analysis. The change in polarizability values with halogen substitutions were  
39 calculated. The variations of HOMO-LUMO energy values and chemical descriptors  
40 with halogen substitutions were investigated. To foresee the important reactive sites  
41 of the title compound, we combined DFT calculations and molecular dynamics (MD)  
42 and visualized the ALIE and Fukui functions. Sensitive nature of the compound  
43 towards autoxidation and degradation in the presence of water was investigated by  
44 the calculation of BDE and RDF. By molecular docking study the compound forms  
45 a stable complex with ubiquinol-cytochrome-c reductase inhibitor.

46

47 **Keywords:** Quinoline, DFT, ALIE, RDF, BDE, Molecular Docking

48

## 49 **1. Introduction**

50

51 Quinoline derivatives possess number of medicinal properties like anti-bacterial [1] anti-filarial  
52 [2] anti-malarial [3,4] anti-fungal [5] cardiovascular [1] anti-tuberculosis [6]. 8-hydroxy  
53 quinoline derivative can be used as an active compound of pharmaceutical products [7] nuclear  
54 medicine [8] treating cancer [1] and neurodegeneration disorder [9]. Recent years DFT,  
55 molecular docking and vibrational studies of quinoline derivatives are reported [10]. Some  
56 quinoline derivatives are used as lifesaving drugs and have many applications like optical  
57 switches sensors in electro chemistry and in the area of inorganic chemistry [11,12]. Amino  
58 quinoline derivatives are a good candidate for the inhibition of human immuno virus (HIV)  
59 [13]. In order to analyse the effect of halogen substitution, in the parent molecule the hydrogen  
60 atoms 7H, 8H and 9H are replaced by fluorine, chlorine and bromine atoms which are  
61 designated as 7F, 8F, 9F for fluorine, 7Cl, 8Cl, 9Cl for chlorine and 7Br, 8Br, 9Br for bromine,  
62 respectively. Here we have spectroscopically characterized the title compound by employing  
63 FT-IR and FT-Raman techniques and to predict the local as well as global reactive properties  
64 by DFT calculations and MD simulations. Using DFT calculations we have also calculated the  
65 Frontier molecular orbitals (FMO) which helps us in understanding the HOMO-LUMO gap  
66 which determines the stability, hardness and many other parameters. To foresee about the  
67 reactive sites ALIE, MEP and Fukui function values are plotted against to the electron density  
68 surface. Thus, we can evaluate the prone sites of electrophilic and nucleophilic attacks. Organic

69 molecules with considerable biological activity and high stability are usually a threat to the  
70 nature [14]. Autoxidation and hydrolysis are important parameters that helps to analyse the  
71 degradation properties of the molecule. BDE (Bond dissociation energy) and RDF (Radial  
72 distribution functions) reflect the sensitivity of compounds towards the water environments,  
73 BDE and RDF can be evaluated using the MD simulations and DFT calculations. The greatest  
74 challenge in the production of pharmaceutical products is to find an active component, if the  
75 active component doesn't meet the requirements, it can be modified using an excipient. Using  
76 solubility parameter, we can easily find out an excipient [15–17]. Therefore, the aim of our  
77 study was to calculate and understand the degradation properties of target molecule, to check a  
78 suitable excipient and to perform molecular docking.

79

## 80 **2. Experimental Details**

81

82 3-[(4-Carboxyphenyl)carbamoyl]-4-hydroxy-2-oxo-1,2-dihydroquinoline-6-carboxylic acid  
83 was prepared by a microwave-assisted reaction of 4-aminobenzoic acid with triethyl  
84 methanetricarboxylate [18] (Scheme 1). All reagents were purchased from Aldrich. Kieselgel  
85 60, 0.040-0.063 mm (Merck, Darmstadt, Germany) was used for column chromatography.  
86 TLC experiments were performed on alumina-backed silica gel 40 F254 plates (Merck). The  
87 plates were illuminated under UV (254 nm) and evaluated in iodine vapour. The melting points  
88 were determined on Boetius PHMK 05 (VEB Kombinat Nagema, Radebeul, Germany) and are  
89 uncorrected. Elemental analyses were carried out on an automatic Perkin-Elmer 240  
90 microanalyser (Boston, USA). The purity of the final compounds was checked by the HPLC  
91 separation module Waters Alliance 2695 XE (Waters Corp., Milford, MA, USA). The detection  
92 wavelength 210 nm was chosen. The peaks in the chromatogram of the solvent (blank) were  
93 deducted from the peaks in the chromatogram of the sample solution. The purity of individual  
94 compounds was determined from the area peaks in the chromatogram of the sample solution.  
95 UV spectra ( $\lambda$ , nm) were determined on a Waters Photodiode Array Detector 2996 (Waters  
96 Corp.) in ca  $6 \times 10^{-4}$  mol methanolic solution and  $\log \epsilon$  (the logarithm of molar absorption  
97 coefficient  $\epsilon$ ) was calculated for the absolute maximum  $\lambda_{\max}$  of individual target compounds.  
98 All  $^1\text{H}$  NMR spectra were recorded on a Bruker AM-500 (499.95 MHz for  $^1\text{H}$ ), Bruker Bio  
99 Spin Corp., Germany. Chemicals shifts are reported in ppm ( $\delta$ ) to internal  $\text{Si}(\text{CH}_3)_4$ , when  
100 diffused easily exchangeable signals are omitted.


101

102

103 2.1 3-[(4-Carboxyphenyl) carbamoyl]-4-hydroxy-2-oxo-1, 2-dihydroxy quinoline-

104 6-carboxylic acid.

105



106

107

108 **Scheme 1.** Preparation of the target compound: (a) microwave irradiation

109

110 4-Aminobenzoic acid (0.7 g, 0.005 mol) was mixed with triethyl methanetricarboxylate (2.12

111 mL, 0.01 mol) and heated in microwave reactor at 50% of power during 15 min and 3 min at

112 90%. The temperature reached 231 °C during heating. Et<sub>2</sub>O was added to the cooled mixture

113 and the precipitate was washed with hot (55 °C) MeOH to obtain the pure product as a yellow

114 crystalline compound. Yield 62%. Mp 340-350 °C. Anal. Calc. for C<sub>18</sub>H<sub>12</sub>N<sub>2</sub>O<sub>7</sub> (368.29): C

115 58.70%, H 3.28%; found: C 58.09%, H 3.54%. HPLC purity 97.52%. UV (nm), λ<sub>max</sub>/log ε:

116 251.3/3.53. IR (cm<sup>-1</sup>): 3621, 1180 (OH), 3034 (CH<sub>arom</sub>), 2970, 1689 (acid), 1680 (lactam), 1642

117 (C=O), 1635 (C = C<sub>cycle</sub>), 1630 (amide), 1599 (Ph), 1520 (NH). <sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>, 500 MHz)

118 δ: 7.41 (d, *J*=8.5 Hz, 1H), 7.70 (d, *J*=9.1 Hz, 2H), 7.90 (d, *J*=9.1 Hz, 2H), 8.15 (d, *J*=8.5 Hz,

119 1H), 8.50 (s, 1H), 12.40 (s, 1H), 12.95 (s, 1H), 16 (s, 1H). The FT-IR spectrum (Fig. 1) was

120 recorded using KBr pellets on a DR/Jasco FT-IR 6300 spectrometer. The FT-Raman spectrum

121 (Fig. 2) was obtained on a Bruker RFS 100/s, Germany. For excitation of the spectrum the

122 emission of Nd: YAG laser was used, excitation wavelength 1064 nm, maximal power 150mW,

123 measurement on solid sample.

124

### 125 3. Computational Details

126

127 Calculations of the wavenumbers, molecular geometry, polarizability values, frontier

128 molecular orbital analysis were carried out with Gaussian 09 program [19] using the B3LYP/

129 6-31G(d) quantum chemical calculation method. A scaling factor of 0.9613 is used to scale the

130 theoretically obtained wavenumbers [20] and the assignments of the vibrational wavenumbers

131 are done by using Gauss View [21] and GAR2PED software [22]. Parameters corresponding

132 to optimized geometry of the title compound (Fig. 3) are given in Table 1. Jaguar 9.0 and

133 Schrodinger materials science suite 2015-4 was used for the investigation of the reactivity of  
134 the compound [23]. DFT calculations with the Jaguar were carried out using B3LYP exchange  
135 correlation functional, with 6-311++G(d,p), 6-31+G(d,p) and 6-311G(d,p) basis sets for the  
136 calculations of ALIE, Fukui functions and BDEs, respectively. Desmond program was used for MD  
137 simulations which was performed by OPLS 2005 force field [24], with simulation time set to 10 ns.  
138 The pressure was set at 1.0325 bar while temperature was set to 300 K. Cutoff radius was set to 12 Å,  
139 while the modelled system was of isothermal-isobaric (NPT) ensemble class. For the solvent of SPC  
140 model [25] was used here. For the modelling of system CPCHODQ6C molecule was placed alone into  
141 the cubic box with ~3000 water molecules. For the preparation of input files and output analysis  
142 Schrodinger materials science suite 2015-4 was used [26].

143

## 144 **4. Results and Discussions**

145

### 146 *4.1 Optimized Geometrical Parameters*

147

148 As far as we know, no X-ray crystallographic data of the title compound has yet been reported.  
149 However, the theoretical results (DFT) obtained are nearly comparable with the reported  
150 structural parameters of similar derivatives. For the title compound the bond lengths of C<sub>2</sub>-C<sub>3</sub> =  
151 1.4084 Å, C<sub>3</sub>-C<sub>4</sub> = 1.4130 Å and C<sub>4</sub>-C<sub>5</sub> = 1.4045 Å and these values are greater than that of C<sub>1</sub>-  
152 C<sub>2</sub> (1.3824 Å) and C<sub>5</sub>-C<sub>6</sub> (1.3916 Å) due to adjacent quinoline ring and the reported values are  
153 C<sub>2</sub>-C<sub>3</sub> = 1.4020 Å, C<sub>3</sub>-C<sub>4</sub> = 1.4171 Å, C<sub>5</sub>-C<sub>4</sub> = 1.4043 Å [27] and C<sub>2</sub>-C<sub>3</sub>=1.4121 Å, C<sub>3</sub>-  
154 C<sub>4</sub>=1.4079 Å and C<sub>5</sub>-C<sub>4</sub>=1.4045 Å respectively [28]. The values of bond lengths C<sub>12</sub>-C<sub>14</sub>  
155 (1.4579 Å) and C<sub>14</sub>-C<sub>18</sub> (1.4854 Å) are high which is due to the adjacent C=O and carbamoyl  
156 groups. Ranjith *et al* reported the corresponding values as C<sub>13</sub>-C<sub>15</sub>=1.4711 Å and C<sub>15</sub>-  
157 C<sub>19</sub>=1.4686 Å.[28]. The bond angle C<sub>3</sub>-C<sub>4</sub>-C<sub>5</sub> (119.5°) is lesser than 120° because of the  
158 presence of quinoline ring. The angles C<sub>4</sub>-C<sub>13</sub>-C<sub>14</sub> and C<sub>3</sub>-N<sub>10</sub>-C<sub>12</sub> are 121.2° and 126.0°  
159 respectively, which can be assumed as due to the presence of OH group which is  
160 electropositive. According to literature the corresponding reported bond angles are C<sub>1</sub>-C<sub>2</sub>-C<sub>3</sub>  
161 (119.6°), C<sub>2</sub>-C<sub>3</sub>-C<sub>4</sub> (119.4°), C<sub>2</sub>-N<sub>14</sub>-C<sub>20</sub> (125.8°), C<sub>3</sub>-C<sub>15</sub>-C<sub>18</sub> (121.3°) and N<sub>14</sub>-C<sub>20</sub>-C<sub>18</sub> (114.2°)  
162 respectively [29]. The presence of higher electro negative group C=O would be the reason for  
163 the lesser bond angle of N<sub>10</sub>-C<sub>12</sub>-C<sub>14</sub> (116.0°). The reported bond angle of N<sub>11</sub>-C<sub>13</sub>-C<sub>15</sub> as 114.3°  
164 [28]

165

166

## 167 4.2 IR and Raman Spectra

168

169 The observed IR and Raman bands and calculated (scaled) wavenumbers and assignments are  
170 given in Table 2. The  $C_{12}=O_{16}$  and  $C_{13}=C_{14}$  stretching vibrations are assigned at  $1678\text{ cm}^{-1}$   
171 (DFT),  $1670\text{ cm}^{-1}$  (IR) and at  $1562\text{ cm}^{-1}$  (DFT),  $1551\text{ cm}^{-1}$  (IR),  $1548\text{ cm}^{-1}$  (Raman)  
172 respectively. The C=O stretching vibration in the spectra of carboxylic acid give rise to strong  
173 bands in the region  $1600\text{-}1700\text{ cm}^{-1}$  [30]. The bands observed at  $1746, 1741\text{ cm}^{-1}$  theoretically  
174 are assigned as  $C_{35}=O_{36}, C_{31}=C_{32}$  stretching modes of the title compound. The stretching band  
175 of  $C_{13}-O_{15}$  is expected in the region  $1220 \pm 40\text{ cm}^{-1}$  [31–33] and the band at  $1292\text{ cm}^{-1}$  (DFT)  
176 is assigned as C-O stretching vibration of the title compound while the reported value is  $1206$   
177  $\text{cm}^{-1}$  (DFT) [31]. The O-H stretching vibration gives rise to a band at  $3050 \pm 150\text{ cm}^{-1}$  [30]. The  
178 band observed at  $2666\text{ cm}^{-1}$  experimentally and  $2793\text{ cm}^{-1}$  in DFT calculation is assigned as  
179 the O-H stretching vibration. The downshift of the OH stretching mode is due to the strong  
180 hydrogen bonded system present in the title compound as reported in literature [34]. The O-H  
181 in-plane and out-of-plane deformation modes are expected at  $1395 \pm 55\text{ cm}^{-1}$  and at  $905 \pm 70$   
182  $\text{cm}^{-1}$  respectively [30]. For the title compound the band at  $1352\text{ cm}^{-1}$  (DFT) is assigned as the  
183 in-plane O-H deformation band. Similarly, the band at  $922\text{ cm}^{-1}$  (DFT) is assigned as the O-H  
184 out-of-plane deformation band of the title compound. Rajeev et al. [29] reported a band at  
185  $1412\text{ cm}^{-1}$  as the in-plane O-H deformation. The N-H stretching vibrations are expected [35]  
186 in the range  $3500\text{-}3300\text{ cm}^{-1}$ . In the present study the bands observed at  $3440, 3392\text{ cm}^{-1}$  in the  
187 IR spectrum and  $3454\text{ cm}^{-1}$  theoretically are assigned as N-H stretching vibrational mode In  
188 the present case the N-H stretching mode splits into a doublet and downshifted from the  
189 computed value which indicates the weakening of the N-H bond [36,37]. N-H group shows  
190 bands at  $1510\text{-}1500, 1350\text{-}1250$  and  $740\text{-}730\text{ cm}^{-1}$  [37]. According to literature if N-H is a part  
191 of a closed ring [38] the N-H deformation band is absent in the region  $1510\text{-}1500\text{ cm}^{-1}$ . In the  
192 present case the N-H in-plane deformation band is observed at  $1439\text{ cm}^{-1}$  theoretically. The  
193 out-of-plane deformation bands of N-H are expected in the range  $650 \pm 50\text{ cm}^{-1}$  and the bands  
194 observed at  $612\text{ cm}^{-1}$  (DFT) are assigned as  $\gamma$ N-H mode of the title compound. In the present  
195 case, the quinoline CC stretching ring modes are observed at  $1413\text{ cm}^{-1}$  in the IR spectrum,  
196  $1414\text{ cm}^{-1}$  in the Raman spectrum,  $1413\text{ cm}^{-1}$  theoretically with high Raman activity and the  
197 C-N stretching modes are at  $1114\text{ cm}^{-1}$  in the IR spectrum,  $1233, 1106, 1082\text{ cm}^{-1}$  theoretically.  
198 Rajeev et al. reported the quinoline stretching modes at  $1610, 1445, 1020\text{ cm}^{-1}$  (C-C),  $1262$   
199  $\text{cm}^{-1}$  (C-N) in the IR spectrum,  $1609, 1051, 1022\text{ cm}^{-1}$  (C-C),  $1202\text{ cm}^{-1}$  (C-N) in the Raman  
200 spectrum,  $1607, 1433, 1045, 1035\text{ cm}^{-1}$  (C-C),  $1270, 1230\text{ cm}^{-1}$  (C-N) theoretically [29]. The

201 DFT calculations give the C-H stretching modes of the phenyl ringI and phenyl ringII of the  
202 title compound at 3128, 3101, 3067  $\text{cm}^{-1}$  and 3151, 3099, 3098, 3061  $\text{cm}^{-1}$ . Similarly, the bands  
203 observed at 3132, 3103, 3078  $\text{cm}^{-1}$  (Raman) and 3157, 2990  $\text{cm}^{-1}$  (IR) are assigned as C-HI  
204 and C-HII stretching modes of the phenyl rings of parent molecule [30]. The bands observed  
205 at 1470, 1372 and 1593, 1505, 1314  $\text{cm}^{-1}$  in IR spectrum, 1477 and 1602, 1503, 1382, 1323  $\text{cm}^{-1}$   
206  $\text{cm}^{-1}$  in Raman spectrum and at 1618, 1580, 1485, 1369, 1342 and 1609, 1591, 1538, 1403, 1321  
207  $\text{cm}^{-1}$  theoretically are assigned as phenyl rings stretching modes of the title compound which  
208 are expected in the region 1620-1250  $\text{cm}^{-1}$  [30]. In asymmetric tri-substituted benzene, when  
209 all the three substituents are heavy, the ring breathing mode appears above 1100  $\text{cm}^{-1}$  [31]. For  
210 the tri-substituted phenyl ring PhI, the ring breathing mode is assigned at 1066  $\text{cm}^{-1}$   
211 theoretically. Madhavan et al. [39] reported the ring breathing mode for a compound having  
212 two tri-substituted benzene rings at 1110 and 1083  $\text{cm}^{-1}$  respectively. In the present case, the  
213 bands observed at 1070  $\text{cm}^{-1}$  in Raman spectrum and 1072  $\text{cm}^{-1}$  theoretically are assigned as  
214 the ring breathing mode of the phenyl ring II which is expected in region 1020-1070  $\text{cm}^{-1}$  [32].  
215 Panicker et al. [40] reported the ring breathing mode of di-substituted benzene at 1018  $\text{cm}^{-1}$   
216 (IR), 1034  $\text{cm}^{-1}$  (Raman) and 1019  $\text{cm}^{-1}$  (DFT). For the title compound, the bands observed at  
217 1284  $\text{cm}^{-1}$  (IR), 1134, 1099,  $\text{cm}^{-1}$  (Raman) and 1288, 1245, 1152, 1137, 1104  $\text{cm}^{-1}$  (DFT) are  
218 assigned as the C-H in-plane bending modes of the phenyl rings. The C-H out-of-plane  
219 deformations are expected below 1000  $\text{cm}^{-1}$ [31] and for the title compound the theoretical  
220 calculations give bands at 951, 949, 938, 925, 842, 828, 815, 794  $\text{cm}^{-1}$  as  $\gamma$ C-H modes of the  
221 phenyl rings. Experimentally these bands are observed at 970, 926, 841, 818, 799  $\text{cm}^{-1}$  in the  
222 Raman spectrum.

223

#### 224 4.3 Frontier Molecular Orbitals

225

226 Frontier molecular orbital study is used to explain the chemical behaviour and stability of the  
227 molecular system. The atomic orbital components of the frontier molecular orbitals are shown  
228 in (Fig. 4A, 4B, 4C, 4D). The delocalization of HOMO and LUMO over the molecular system  
229 shows the charge transfer within the molecular system. The HOMO-LUMO gap for  
230 CPCHODQ6C is found to be 2.646 eV. The chemical descriptors can be evaluated by using  
231 HOMO and LUMO orbital energies,  $E_{\text{HOMO}}$ , and  $E_{\text{LUMO}}$  as ionization energy  $I = -E_{\text{HOMO}}$ ,  
232 electron affinity  $A = -E_{\text{LUMO}}$ , hardness  $\eta = (I-A)/2$ , chemical potential  $\mu = -(I+A)/2$  and  
233 electrophilicity index  $\omega = \mu^2/2\eta$  [41,42]. According to Kohn-Sham model,  $I = -E_{\text{HOMO}} = 1.001$   
234  $[-E_{\text{HOMO}}(\text{LBS})] -0.05$  eV and  $A = -E_{\text{LUMO}} = 1.0729 [-E_{\text{LUMO}}(\text{LBS})] -0.181$  eV [43]. For the



235 title compound CPCHODQ6C,  $I = 8.54$ ,  $A = 5.894$ ,  $\eta = 1.323$ ,  $\mu = -7.217$  and  $\omega = 19.684$  eV.  
236 The  $I$ ,  $A$ ,  $\eta$ ,  $\mu$  and  $\omega$  values for halogen substituted CPCHODQ6C are tabulated in Table 3.  
237 For the title molecule (Fig. 4D) HOMO is delocalized over the phenyl group (PhII), amide  
238 group and partially over the quinoline ring while the LUMO is delocalized strongly over the  
239 entire molecule except carboxyl group of quinoline ring. For 7Cl (Fig. 4B) HOMO is  
240 delocalized strongly over the quinoline ring and substituted chlorine atom while LUMO is  
241 delocalized strongly over the entire molecule except NH groups. For 8Cl and 9Cl (Fig. 4B)  
242 HOMO is over the phenyl ring PhI and partially over the pyridine ring and LUMO is over the  
243 entire molecule except carboxyl group of PhI and carbonyl group of pyridine ring. For 7Br  
244 (Fig. 4C) HOMO is over the entire molecule except carboxyl group of PhI and LUMO is over  
245 the entire molecule. For 8Br and 9Br (Fig. 4C) HOMO is over the entire molecule except  
246 carboxyl group of PhI and carbonyl group of pyridine ring and LUMO is over the entire  
247 molecule except carboxyl group of PhI and NH group of pyridine ring. For 7F (Fig. 4A)  
248 HOMO is over the entire molecule except carboxyl group of PhI and NH of pyridine while  
249 LUMO is over the entire molecule except NH group of amide group. For 8F (Fig. 4A) HOMO  
250 is over the entire quinoline ring while for 9F (Fig. 4A) HOMO is over the entire molecule.  
251 LUMO is delocalized over the entire molecule except carboxyl group of PhI, carbonyl group  
252 of pyridine and NH group of amides for 8F and 9F. The chemical potential decreases for the  
253 halogen substitution in the order  $7Cl, 8Cl, 9Cl < 7F, 8F, 9F < 7Br, 8Br, 9Br < CPCHODQ6C$   
254 (Table 3) Chemical potential value of 8Cl is deviated maximum from the parent molecule  
255 while all other halogen substitution shows minimum deviation. Halogen substitution results in  
256 reduction in the  $\mu$  value in comparison with the parent molecule and for 8Cl it is minimum.  
257 Halogen substitution also results a decrease in electrophilicity index and is minimum for 8Cl.  
258 Global hardness is higher for 8Cl because of its large HOMO-LUMO gap which results a  
259 decrease in polarizability.

260

#### 261 4.4 Molecular Electrostatic Potential

262

263 Molecular electrostatic potential and electron density are related to each other to find the  
264 reactive sites for electrophilic and nucleophilic sites [44,45]. The negative (red and yellow)  
265 regions of MEP maps were related to electrophilic reactivity while the positive (blue) regions  
266 to nucleophilic reactivity. For the parent molecule (Fig. 5D) most electrophilic (red and  
267 Yellow) regions are C=O group of both carboxyl group, slightly over PhII and the nucleophilic  
268 regions (blue) are deeply over the NH bond of quinoline ring, slightly over the hydrogen atom

269 of the OH groups. For 7Cl, 8Cl and 9Cl (Fig. 5B) electrophilic regions are strongly over the  
270 carbonyl group of both carboxyl group and slightly over the phenyl ring while the nucleophilic  
271 regions are over the NH group of quinoline ring and slightly over the hydrogen atoms of the  
272 OH groups and more intense in the case of 8Cl. For fluorine substitution (Fig. 5A) the  
273 electrophilic regions are similar to that of chlorine substitution while the nucleophilic regions  
274 are same that of chlorine substitution but blue region of NH bond of quinoline in 8F is more  
275 pronounced. For bromine substitution (Fig. 5C) also the electrophilic and nucleophilic  
276 behaviour is identical to that of chlorine and fluorine substitution while blue region around  
277 bromine is higher than that in fluorine substitution. The nucleophilic region of fluorine  
278 substitution is less than that in chlorine and bromine substitution.

279

#### 280 4.5 NBO Analysis

281

282 The natural bond orbitals (NBO) calculations were performed using NBO 3.1 program [46]  
283 and the important interactions are presented in Tables 4 and 5. The strong interactions are  
284  $LPO_{37} \rightarrow C_{35}-O_{36}$ ,  $LPO_{36} \rightarrow C_{35}-O_{37}$ ,  $LPO_{33} \rightarrow C_{31}-O_{32}$ ,  $LPO_{32} \rightarrow C_{31}-O_{33}$ ,  $LPN_{20} \rightarrow C_{18}-O_{19}$ ,  
285  $LPO_{15} \rightarrow C_{13}-C_{14}$ ,  $LPN_{10} \rightarrow C_{12}-O_{16}$ ,  $LPC_4 \rightarrow C_{13}-C_{14}$  and  $LPC_4 \rightarrow C_5-C_6$  with energies, 21.44,  
286 16.30, 21.43, 16.26, 28.99, 22.49, 27.67, 37.81 and 35.28 kcal/mol. 100% p-character is found  
287 in lone pairs of  $O_{37}$ ,  $O_{36}$ ,  $O_{33}$ ,  $O_{32}$ ,  $O_{16}$ ,  $O_{15}$  and  $N_{10}$  atoms.

288

#### 289 4.6 Nonlinear Optical Properties

290

291 The calculated first hyper polarizability of the title compound is  $15.827 \times 10^{-30}$  esu which is  
292 121.75 times that of standard NLO material urea ( $0.13 \times 10^{-30}$  esu) (Table 6) [47]. The reported  
293 value of first hyper polarizability of similar derivative is  $2.24 \times 10^{-30}$  esu [48]. The phenyl ring  
294 stretching vibrations at 1593, 1505  $\text{cm}^{-1}$  in the IR spectrum have their counterparts in the  
295 Raman spectrum at 1602, 1503  $\text{cm}^{-1}$  respectively with IR and Raman intensities are  
296 comparable. These types of organic molecules have conjugated  $\pi$ -electron system and large  
297 hyper polarizability which leads to nonlinear optical properties [49]. The C–N distances in the  
298 calculated molecular structure vary from 1.3745 to 1.4047 Å which are in between those of a  
299 CN single and double bond and this suggest an extended  $\pi$ -electron delocalization over the  
300 molecular system which is also responsible for the nonlinearity of the molecule [50]. We  
301 conclude that the title compound is an attractive object for future studies of non-linear optical  
302 properties.

303

#### 304 4.7 ALIE surfaces and Fukui functions

305

306 Average local ionization energy (ALIE) is a quantum molecular descriptor which indicates the  
307 energy required to remove an electron from the molecule. So, we can say that the sites with  
308 least values of ALIE are more open for an electrophilic attack [51,52]. According to the  
309 equation given below ALIE is the sum of orbital energies weighted by the orbital density.

$$310 \quad I(r) = \sum_i \frac{\rho_i(\vec{r})\varepsilon_i}{\rho(\vec{r})} \quad (1)$$

311 Where  $\rho_i(\vec{r})$  denotes electronic density of the i-th molecular orbital at the point  $\vec{r}$ ,  $\varepsilon_i$  denotes  
312 orbital energy and  $\rho(\vec{r})$  denotes total electronic density function. We have mapped the ALIE  
313 values with the electron density surface in order to understand the attacking sites of  
314 electrophiles. The ALIE figure is represented in Fig. 6. Here in this figure, we can see that  
315 benzene ring shows the least ALIE values that is 210.59 kcal/mol. On the other side in the close  
316 vicinity of hydrogen atoms H<sub>11</sub>, H<sub>17</sub>, H<sub>34</sub>, H<sub>38</sub>, H<sub>39</sub> shows highest ALIE value 372.51 kcal/mol.  
317 The interesting molecular sites which are important in the view of local reactivity can be  
318 identified using Fukui functions. The functional derivative of chemical potential with respect  
319 to external potential is termed as Fukui functions. According to Maxwell's relations we can  
320 interpret this as the derivative of electronic density with respect to the number of electrons  
321 [53–55]. If we physically interpret the term, it is the change in electron density according to  
322 change in charge. These functions in Jaguar program are calculated with the help of finite  
323 difference approach, according to the following equations:

$$324 \quad f^+ = \frac{(\rho^{N+\delta}(r) - \rho^N(r))}{\delta} \quad (2)$$

$$325 \quad f^- = \frac{(\rho^{N-\delta}(r) - \rho^N(r))}{\delta} \quad (3)$$

326 where  $N$  stands for the number of electrons in reference state of the molecule, while  $\delta$  stands  
327 for the fraction of electron which default value is set to be 0.01[55]. By plotting Fukui functions  
328 to electron density surfaces we get a lot of information about the important molecular sites  
329 acting as a reactive centre [51,52]. The Fukui function plot is represented in Fig. 7. The colour

330 coding in the plot is as follows, purple (positive) colour in Fukui function  $f^+$  means the electron  
331 density has been increased by the addition of charges to the system while red (negative) colour  
332 in Fukui function  $f^-$  means the electron density has been diminished by the addition of charges.  
333 Electron density is increased in the near vicinity of carbon atom  $C_{21}$  and electron density is  
334 decreased near the  $O_{16}$ ,  $O_{36}$ ,  $O_{37}$  atoms.

335

#### 336 4.8 *Reactive and degradation properties based on autoxidation and hydrolysis*

337

338 Degradation properties based on autoxidation and hydrolysis mechanisms are explained using  
339 RDFs and BDEs. Calculations of BDE for hydrogen abstraction allow the possibility to predict  
340 molecular sites where autoxidation process could start. It provides details about upto what  
341 extent some molecule are sensitive to presence of oxygen in open air, a parameter that is of  
342 very much importance in pharmaceutical industry. Forced degradation studies can also be  
343 studied using BDE, since they can be used for confirmation and determination of degradation  
344 path of some organic pharmaceutical molecule [56–58]. Wright et al. says that the target  
345 molecule is most vulnerable to autoxidation if the BDE for hydrogen abstraction ranges from  
346 70 to 85 kcal/mol [59]. BDE values for hydrogen abstraction lower than 70 kcal/mol, are not  
347 suitable for the autoxidation mechanism since formed radicals are resistant for  $O_2$  insertion  
348 [60–62]. Fig. 8 contains all BDE values for CPCHODQ6C. Red coloured values represent the  
349 BDE values for hydrogen abstraction and blue-coloured values correspond to the BDE values  
350 for the rest of the single acyclic bonds. All the BDE values of molecule are greater than 100  
351 kcal/mol so we can say that the molecule is stable in the presence of oxygen. To find the extend  
352 of hydrolysis we have also calculated the RDF for the molecule. In Fig. 9 RDFs of atoms with  
353 the most pronounced interactions with water molecules are presented. In RDF plot,  $g(r)$   
354 represents the probability of finding a particle in the distance  $r$  from another particle [63].  
355 Results provided in Fig. 9 indicate that only ten atoms of CPCHODQ6C molecule have  
356 relatively significant interactions with water molecules. These atoms are  $C_{12}$ ,  $C_{24}$ ,  $O_{19}$ ,  $O_{33}$ ,  
357  $O_{37}$ ,  $H_{11}$ ,  $H_{17}$ ,  $H_{34}$ ,  $H_{38}$ ,  $H_{39}$  which shows similar  $g(r)$  profile. According to the maximal  $g(r)$   
358 values the most important RDF is certainly for  $H_{34}$  atom. Here the presence of hydrogen atoms  
359 shows the low stability of the molecule in the surroundings of water, so the role of this title  
360 compound in the pharmaceutical industry is irrelevant.

361

#### 362 4.9 Solubility parameter

363

364 One of the demanding fields in pharmaceutical is the development of new products and finding  
365 the active component. To be considered for the pharmaceutical drug production, the active  
366 ingredient has to fit in to certain physical properties such as stability, solubility etc. If the active  
367 component doesn't meet the required parameters, then these properties must be modified. One  
368 way to modify the properties without structural modification is to find a suitable excipient and  
369 mixing them up. Suitable excipient can be identified using experimental methods but its time  
370 consuming, while computational methods can be effectively used to narrow down the  
371 possibilities. Active component and excipient must be mutually compatible, one of the  
372 parameters for compatibility is the solubility parameter. Which means, the solubility parameter  
373 of the active component must have a value similar to the one of the excipient compounds  
374 [15–17]. Solubility parameter can be computationally predicted by applying the MD  
375 simulations and the following equation:

$$376 \quad \delta = \sqrt{\frac{\Delta H_V - RT}{V_m}} \quad (1)$$

377 In this work, the solubility parameter has been calculated for the CPCHODQ6C molecule and  
378 it has been compared with three compounds frequently used as excipients polyvinylpyrrolidone  
379 polymer (PVP), maltose, and sorbitol). MD systems used to calculate this quantity consisted  
380 of 32 molecules placed in a cubic simulation box. Solubility parameters of all mentioned  
381 compounds have been summarized in Table 7. As indicated by the results presented in Table  
382 7, the CPCHODQ6C molecule has the highest compatibility with the Maltose compound. In  
383 this case, the difference between corresponding values of solubility parameter is less than 0.2  
384 MPa<sup>1/2</sup>, indicating very high compatibility. Solubility parameter of sorbitol is higher than the  
385 solubility parameter of the CPCHODQ6C molecule, while PVP has lesser value than our title  
386 molecule. Therefore, the MD calculations suggest that it is reasonable to consider Maltose as  
387 an excipient for CPCHODQ6C molecule.

388

#### 389 4.10 Molecular Docking

390

391 Antimalarial drugs constitute a major part of antiprotozoal drugs. Malaria remains a major  
392 health problem, mainly in sub-Saharan Africa and parts of Asia and South America [64] with  
393 over 200 million clinical infections and nearly half a million deaths annually. Malaria is caused

394 by protozoan parasites belonging to the genus *Plasmodium* and is transmitted via the bite of a  
395 female *Anopheles* mosquito. There are four major species of the parasite that cause malaria in  
396 humans, namely, *Plasmodium falciparum*, *P. vivax*, *P. ovale* and *P. malaria*, while a fifth  
397 parasite, *P. knowlesi*, is now recognized [65]. Historically, a range of drugs has been used to  
398 treat or prevent malaria, including several derived from the quinoline ring system such as  
399 quinine, chloroquine (CQ), amodiaquine, piperazine, mefloquine, and primaquine [66].  
400 Quinoline and its related derivative comprise a class of heterocycles, which has been exploited  
401 immensely than any other nucleus for the development of potent antimalarial agents. Various  
402 chemical modifications of quinoline have been attempted to achieve analogs with potent  
403 antimalarial properties against sensitive as well as resistant strains of *Plasmodium* sp., together  
404 with minimal potential undesirable side effects [67]. From PASS (Prediction of Activity  
405 Spectra) [68] analysis we have to choose the favorable target for docking study and different  
406 types of activities predicted as in Table 8. We choose the activity ubiquinol-cytochrome-c  
407 reductase inhibitor with Pa value 0.858 and high-resolution crystal structure of corresponding  
408 receptor atovaquone-inhibited cytochrome BC1 complex with (PDB ID: 4PD4) was  
409 downloaded from the RCSB protein data bank website. Atovaquone is a drug that inhibits the  
410 respiratory chain of *Plasmodium falciparum*, but with serious limitations like known resistance,  
411 low bioavailability and high plasma protein binding [69]. cyt bc1 inhibitors are generally  
412 classified as slow-onset anti-malarials, we found that a single dose of endochin-like quinolone-  
413 400 (ELQ-400) rapidly induced stasis in blood-stage parasites, which was associated with a  
414 rapid reduction in parasitemia in vivo. ELQ-400 also exhibited a low propensity for drug  
415 resistance and was active against atovaquone-resistant *P. falciparum* strains with point  
416 mutations in cyt bc1. ELQ-400 shows that cyt bc1 inhibitors can function as single-dose, blood-  
417 stage anti-malarials and is the first compound to provide combined treatment, prophylaxis, and  
418 transmission blocking activity for malaria after a single oral administration [70]. This  
419 remarkable efficacy suggests that metabolic therapies, including cyt bc1 inhibitors, may be  
420 valuable additions to the collection of single-dose anti-malarials in current development. All  
421 docking calculations were performed on AutoDock4.2 [71], Auto Dock-Vina software [72] and  
422 as in literature [73]. The amino acids of the receptor Tyr275, Asn96, Asn271 forms H-bond  
423 with OH group and other electrostatic interactions are detailed in Fig. 10. The docked ligand  
424 forms a stable complex with the receptors atovaquone-inhibited cytochrome BC1 complex as  
425 depicted in Fig. 11 and the binding free energy value is -9.1 kcal/mol (Table 9). The docked  
426 ligand is embedded with the catalytic site of cytochrome BC1 complex as shown in Fig. 12.  
427 These preliminary results suggest that the compound having inhibitory activity against the

428 antimalarial receptor atovaquone–inhibited cytochrome BC1 complex. Thus, the title  
429 compound can be developed as drug used for the treatment of malaria.

430

#### 431 4.11 Drug-Likeness Study

432

433 The drug-likeness characteristics of the CPCHODQ6C molecule were predicted using  
434 validated free web tool SwissADME [74]. The results were tabulated as in Table 10. According  
435 to Lipinski *et al* [75] the title compound must have 5 special features as follows 1-  $MlogP \leq 5$ ,  
436 2- molecular weight (MW)  $\leq 500$  gm/mol, 3-number of H-bond acceptor (HBA)  $\leq 10$  and  
437 number of H-Bond donors (HBD)  $\leq 5$ , 4- number of rotatable bonds (nRot)  $\leq 10$  and 5-  
438 topological Polar Surface Area (TPSA)  $< 140 \text{ \AA}^2$ . From the Table 10 our synthesized compound  
439 shows good agreement with the criteria stated by Lipinski rules. Bioavailability radar of the  
440 CPCHODQ6C was created using SwissADME (Fig. 13) and shows that the compound has a  
441 moderate water solubility and low gastrointestinal absorption. Hence it may not be suitable for  
442 oral administration.

443

## 444 5 Conclusions

445

446 The vibrational spectroscopic studies of 3-[(4-carboxyphenyl) carbamoyl]-4-hydroxy-2-oxo-1,  
447 2-dihydroquinoline-6-carboxylic acid in the ground state were reported theoretically and  
448 experimentally. Potential energy distribution of normal mode vibration was done using  
449 GAR2PED programme. The vibrational wave number of the title compound successfully  
450 analysed. For the title compound HOMO is delocalized over the phenyl group, amide group  
451 and LUMO is over the entire molecule except carboxyl group of quinoline ring. In addition to  
452 that the halogen substituted HOMO-LUMO calculation showed a decrease in the  
453 electrophilicity index and is minimum for substituted chlorine at the eighth position of the  
454 compound. The molecular electrostatic potential analysis results that the negative charge  
455 covers part of the oxygen atom in carboxylic acid and positive charge over the nitrogen atom  
456 in the quinoline ring. NBO analysis predicts a strong interactions  $LPO_{37} \rightarrow C_{35}-O_{36}$ ,  
457  $LPO_{36} \rightarrow C_{35}-O_{37}$ ,  $LPO_{33} \rightarrow C_{31}-O_{32}$ ,  $LPO_{32} \rightarrow C_{31}-O_{33}$ ,  $LPN_{20} \rightarrow C_{18}-O_{19}$ ,  $LPO_{15} \rightarrow C_{13}-C_{14}$ ,  
458  $LPN_{10} \rightarrow C_{12}-O_{16}$ ,  $LPC_4 \rightarrow C_{13}-C_{14}$  and  $LPC_4 \rightarrow C_5-C_6$ . The calculated first hyperpolarizability  
459 of the material is 121.75 times greater than the standard NLO material, so we can say that the  
460 compound is optically active. By DFT calculations we were able to calculate the ALIE values,

461 beside benzene ring, we have determined H<sub>11</sub>, H<sub>17</sub>, H<sub>34</sub>, H<sub>38</sub>, H<sub>39</sub> are prone to electrophilic  
462 attacks. Thanks to the mapping of the Fukui function values to the electron density surface we  
463 have also determined that carbon atom C<sub>21</sub> and O<sub>16</sub>, O<sub>36</sub>, O<sub>37</sub> are important reactive centres.  
464 Calculation of BDE showed that title molecule is not sensitive in the water surroundings  
465 towards auto oxidation mechanisms. The presence of hydrogen atoms in the RDF shows the  
466 low stability of the title compound in the degradation processes. The MD calculations of  
467 solubility parameter suggests that it is reasonable to consider Maltose as an excipient for  
468 CPCHODQ6C molecule. By molecular docking the compound forms a stable complex with  
469 ubiquinol-cytochrome-c reductase inhibitor as is evident from the binding affinity values.

470

### 471 **Acknowledgments**

472

473 Part of this work has been performed with the support from Schrödinger Inc. Authors would  
474 like to extend their appreciation to the department of physics, University of Novi Sad for the  
475 Molecular dynamics simulations.

476

### 477 **References**

478

- 479 [1] Y. Bouzian, K. Karrouchi, Y. Sert, C.H. Lai, L. Hani, N.H. Ahabchane, A. Talbaoui, J.  
480 T. Mague, E.M. Essassi, Synthesis, spectroscopic characterization, crystal structure,  
481 DFT, molecular docking and in vitro antibacterial potential of novel quinoline  
482 derivatives J. Mol. Struct. 1209 (2020) 127940.
- 483 [2] S. Tewari, P.M.S. Chauhan, A.P. Bhaduri, M. Fatima, R.K. Chatterjee, Synthesis and  
484 Anti filarial agents Bioorg. Med. Chem. Lett. 10 (2000) 1409–1412.
- 485 [3] Y. Bouziana, Y. Sert, K. Khalid, L.V. Meervelt, K. Chkiratea, Lhassan Mahi, N.H.  
486 Ahabchane, A. Talbaoui, E.M. Essassi, Synthesis, spectroscopic characterization, DFT,  
487 molecular docking and in vitro antibacterial potential of novel quinoline derivatives, J.  
488 Mol. Struct.1246 (2021) 131217.
- 489 [4] B. Sureshkumar, Y.S. Mary, C.Y. Panicker, S. Suma, Stevan Armaković, Sanja J.  
490 Armaković, C.Van Alsenoy, B. Narayana Quinoline derivatives as possible lead  
491 compounds for anti-malarial drugs: spectroscopic, DFT and MD study, Arab. J.  
492 Chem.13 (2020) 632-648.
- 493 [5] R.F. Hector, An overview of anti-fungal drugs and their use for treatments of deep and  
494 superficial mycoses in animals, Clin. Tech. Small Anim. Pract. 20 (2005) 240–249.



- 495 [6] A. Nayyar, A. Malde, E. Coutinho, R. Jain, Synthesis, anti-tuberculosis activity and  
496 3D-QSAR study of ring-substituted-2/4-quinoline carbaldehyde derivatives, *Bioorg.*  
497 *Med. Chem.* 14 (2006) 7302–7310.
- 498 [7] B. Sureshkumar, Y.S Mary, C.Y. Panicker, K.S. Resmi, S. Suma, S. Armaković, S.J.  
499 Armaković, C. Van Alsenoy. Spectroscopic analysis of 8-hydroxyquinoline-5-  
500 sulphonic acid and investigation of its reactive properties by DFT and molecular  
501 dynamics simulations. *J. Mol. Struct.* 1150 (2017) 540–552.
- 502 [8] G. Bandoli, A. Dolmella, F. Tisato, M. Porchia, F. Refosco Mononuclear six  
503 coordinated Ga (III) complexes, a comprehensive survey *Coord. Chem. Rev.* 253  
504 (2009) 56–77.
- 505 [9] M.J. Hannon, Metal based anticancer drugs, from a past anchored in platinum  
506 chemistry to a post genomic future of diverse chemistry and biology. *Pure Appl. Chem.*  
507 79 (2007) 2243–2261.
- 508 [10] R.T. Ulahannan, C.Y. Panicker, H.T. Varghese, R. Musiol, J. Jampilek, C. Van  
509 Alsenoy, J.A. War, S.K. Srivastava, Molecular structure, FT-IR, FT-Raman, NBO,  
510 HOMO and LUMO, MEP, NLO and molecular docking study of 2-[(E)-2-(2-  
511 bromophenyl)-ethenyl quinoline-6-carboxylic acid *Spectrochim. Acta.* 151 (2015)  
512 184–197.
- 513 [11] S.A. Khan, A.M. Asiri, S.H. Al-Thaqafy, H.M.F. Aidallah, S.A. El-Daly, Synthesis,  
514 characterization and spectroscopic behavior of novel 2-oxo-1,4-disubstituted-1,2,5,6-  
515 tetrahydrobenzo[h]quinoline-3-carbonitrildyes, *Spectrochim. Acta* 133 (2014)  
516 141–148.
- 517 [12] C.B. Sangani, J.A. Makawana, X. Zhang, S.C. Teraiya, I. Lin, H.L. Zhu, Design,  
518 synthesis and molecular modeling of pyrazole-quinoline-pyridine hybrids as a new  
519 class of antimicrobial and anticancer agents, *Eur. J. Med. Chem.* 76 (2014) 549–557.
- 520 [13] V. Arjunana, S. Mohanb, P.S. Balamourougan, P. Ravindran, Quantum chemical and  
521 spectroscopic investigations of 5-aminoquinoline, *Spectrochim. Acta Part A* 74 (2009)  
522 1215–1223.
- 523 [14] S. Armakovic, S.J. Armakovic, J.P. Setrajcic, I.J. Serajcic, Active components of  
524 frequently used  $\beta$ - blockers from the aspect of computational study. *J. Mol. Model*, 18  
525 (2012) 4491–4501.
- 526 [15] D.J. Greenhalgh, A.C. Williams, P. Timmins, P. York, Solubility parameters as  
527 predictors of miscibility in solid dispersions, *J. Pharm. Sci.* 88 (1999) 11821–190.

- 528 [16] R.C. Rowe, Adhesion of film coatings to tablet surfaces a theoretical approach based  
529 on solubility parameters, *Int. J. Pharm.* 41(1988) 219–222.
- 530 [17] R.C. Rowe, Interactions in coloured powders and tablet formulations: a theoretical  
531 approach based on solubility parameters, *Int. J. Pharm.* 53 (1989) 47–51.
- 532 [18] J. Jampilek, R. Musiol, M. Pesko, K. Kralova, M. Vejsova, J. Carroll, A. Coffey, J.  
533 Finster, D. Tabak, H. Niedbala, V. Kozik, J. Polanski, J. Dohnal, Ring-substituted 4-  
534 hydroxy-1H-quinolin-2-ones: Preparation and biological activity. *Molecules*, 14  
535 (2009) 1145–1159.
- 536 [19] Gaussian 09, Revision B.01, M.J. Frisch, G.W. Trucks, H.B. Schlegel, G.E. Scuseria,  
537 M.A. Robb, J. R. Cheeseman, G. Scalmani, V. Barone, B. Mennucci, G.A. Petersson,  
538 H. Nakatsuji, M. Caricato, X. Li, H. P. Hratchian, A.F. Izmaylov, J. Bloino, G. Zheng,  
539 J.L. Sonnenberg, M. Hada, M. Ehara, K. Toyota, R. Fukuda, J. Hasegawa, M. Ishida,  
540 T. Nakajima, Y. Honda, O. Kitao, H. Nakai, T. Vreven, J.A. Montgomery, Jr., J. E.  
541 Peralta, F. Ogliaro, M. Bearpark, J.J. Heyd, E. Brothers, K.N. Kudin, V.N. Staroverov,  
542 T. Keith, R. Kobayashi, J. Normand, K. Raghavachari, A. Rendell, J.C. Burant, S.S.  
543 Iyengar, J. Tomasi, M. Cossi, N. Rega, J.M. Millam, M. Klene, J.E. Knox, J.B. Cross,  
544 V. Bakken, C. Adamo, J. Jaramillo, R. Gomperts, R.E. Stratmann, O. Yazyev, A.J.  
545 Austin, R. Cammi, C. Pomelli, J.W. Ochterski, R.L. Martin, K. Morokuma, V.G.  
546 Zakrzewski, G.A. Voth, P. Salvador, J.J. Dannenberg, S. Dapprich, A.D. Daniels, O.  
547 Farkas, J.B. Foresman, J.V. Ortiz, J. Cioslowski, and D.J. Fox, Gaussian, Inc.,  
548 Wallingford CT, 2010.
- 549 [20] J.B. Foresman, in: E. Frisch (Ed.), *Exploring Chemistry with Electronic Structure*  
550 *Methods: A Guide to Using Gaussian*, Gaussian Inc., Pittsburg, PA, 1996.
- 551 [21] Gauss View, Version 5, R. Dennington, T. Keith, J. Millam, SemichemInc., Shawnee  
552 Mission, KS, 2009.
- 553 [22] J.M.L. Martin, C. Van Alsenoy, GAR2PED, A Program to Obtain a Potential Energy  
554 Distribution from a Gaussian Archive Record, University of Antwerp, Belgium, 2007.
- 555 [23] A.D. Becke, Density-functional thermochemistry. III. The role of exact exchange, *J.*  
556 *Chem. Phys.* 98 (1993) 5648–5652.
- 557 [24] J.L. Banks, H.S. Beard, Y. Cao, A.E. Cho, W. Damm, R. Farid, A.K. Felts, T.A.  
558 Halgren, D.T. Mainz, J.R. Maple, Integrated modelling program, applied chemical  
559 theory (IMPACT), *J. Comput. Chem.* 26 (2005) 1752–1780.

- 560 [25] H.J. Berendsen, J.P. Postma, W.F. van Gunsteren, J. Hermans, Interaction models for  
561 water in relation to protein hydration, in *Intermolecular forces*. 1981, Springer. p.  
562 331–342.
- 563 [26] Schrödinger Release 2015-4: Maestro, version 10.4, Schrödinger, LLC, New York,  
564 NY, 2015.
- 565 [27] J. Chowdhury, M.Ghosh, T.N. Misra, Surface enhanced Raman scattering of 2,2-  
566 biquinoline adsorbed on colloidal silver particles, *Spectrochim. Acta* 56 (2000)  
567 2107–2115.
- 568 [28] P.K. Ranjith, Y. Sheena Mary, C. Yohannan Panicker, P.L. Anto, Stevan Armakovic,  
569 Sanja J. Armakovic, Robert Musiol, Josef Jampilek, C. Van Alsenoy, New quinolone  
570 derivative: Spectroscopic characterization and reactivity study by DFT and MD  
571 approaches, *J. Mol. Struct.* 1135 (2017) 1–14.
- 572 [29] R.T. Ulahannan, C.Y. Panicker, H.T. Varghese, C. Van Alsenoy, R. Musiol, J.  
573 Jampilek, P.L. Anto Spectroscopic (FT-IR, FT-Raman) investigations and quantum  
574 chemical calculations of 4-hydroxy-2-oxo-1,2-dihydroquinoline-7-carboxylic acid  
575 *Spectrochim. Acta* 121 (2014) 404–414.
- 576 [30] N.P.G. Roeges, *A Guide to the Complete Interpretation of the Infrared spectra of*  
577 *Organic Compounds*, Wiley, New York 1994.
- 578 [31] G. Varsanyi, *Assignments of Vibrational Spectra of Seven Hundred Benzene*  
579 *Derivatives*, Wiley, New York 1974.
- 580 [32] N.B. Colthup, L.H. Daly, S.E. Wiberly, *Introduction to IR and Raman Spectroscopy*,  
581 *Academic Press*, New York, 1990.
- 582 [33] R.M. Silverstein, F.X. Webster, *Spectrometric Identification of Organic Compounds*,  
583 ED. 6, John Wiley, Asia, 2003.
- 584 [34] Y.S. Mary, P.J. Jojo, C. Van Alsenoy, M. Kaur, M.S. Siddegowda, H.S. Yathirajan,  
585 H.I.S. Nogueira, S.M.A. Cruz, Vibrational spectroscopic studies (FT-IR, FT-Raman,  
586 SERS) and quantum chemical calculations on cyclobenzaprinium salicylate,  
587 *Spectrochim. Acta* 120 (2014) 340–350.
- 588 [35] L.J. Bellamy, *The IR spectra of Complex Molecules*, John Wiley and Sons, New York  
589 1975.
- 590 [36] S.H.R. Sebastian, M.A. Al-Alshaikh, A.A. El-Emam, C.Y. Panicker, J. Zitko, M.  
591 Dolezal, C. Van Alsenoy, Spectroscopic quantum chemical studies, Fukui functions,  
592 in vitro antiviral activity and molecular docking of 5-chloro-N-(3-nitrophenyl)  
593 pyrazine-2-carboxamide, *J. Mol. Struct.* 1119 (2016) 188–199.

- 594 [37] V.V. Menon, E. Foto, Y.S. Mary, E. Karatas, C.Y. Panicker, G. Yalcin, S. Armakovic,  
595 S.J. Armakovic, C. Van Alsenoy, I. Yildiz, Vibrational spectroscopic analysis,  
596 molecular dynamics simulations and molecular docking study of 5-nitro-2-  
597 phenoxyethyl benzimidazole, *J. Mol. Struct.* 1129 (2017) 86–97.
- 598 [38] G. Socrates, *Infrared Characteristic Group Frequencies*, John Wiley and Sons,  
599 New York, 1981.
- 600 [39] V.S. Madhavan, H.T. Varghese, S. Mathew, J. Vinsova, C.Y. Panicker, FT-IR, FT-  
601 Raman and DFT calculations of 4-Chloro-2-(3,4-dichlorophenyl carbamoyl) phenyl  
602 acetate, *Spectrochim. Acta.* 72 (2009) 547–553.
- 603 [40] C.Y. Panicker, K.R. Ambujakshan, H.T. Varghese, S. Mathew, S. Ganguli, A.K.  
604 Nanda, C. Van Alsenoy, FT-IR, FT-Raman and DFT calculations of 3-[(4-  
605 fluorophenyl)methylene]amino}-2-phenylquinazolin-4(3H)-one, *J. Raman.*  
606 *Spectrosc.* 40 (2009) 527–536.
- 607 [41] A.S. El-Azab, Y.S. Mary, C.Y. Panicker, A.A.-M A-Aziz, A. Magda, El-Sherbeny, C.  
608 Van Alsenoy, DFT and experimental (FT-IR and FT-Raman) investigation of  
609 vibrational spectroscopy and molecular docking studies of 2-(4-oxo-3-phenyl-3,4-  
610 dihydroquinazolin-2-ylthio)-N-(3,4,5 trimethoxy phenyl) acetamide, *J. Mol Struct.*  
611 1113 (2016) 133–145.
- 612 [42] M. Miar, A. Shiroudi, K. Pourshamsian, A.R. Oliaey, F. Hatamjafar, Theoretical  
613 investigations on the HOMO–LUMO gap and global reactivity descriptor studies,  
614 natural bond orbital, and nucleus-independent chemical shifts analyses of 3-  
615 phenylbenzo thiazole-2(3H)-imine and its para-substituted derivatives: Solvent and  
616 substituent effects, *J. Chem. Res.* January-February (2021) 147–158.
- 617 [43] C.G. Zhan, J.A. Nichols, D.A. Dixon, Ionization Potential, Electron Affinity,  
618 Electronegativity, Hardness, and Electron Excitation Energy: Molecular Properties  
619 from Density Functional Theory Orbital Energies, *J. Phys. Chem. A* 107 (2003) 4184-  
620 4195.
- 621 [44] F.J. Luque, J.M. Lopez, M. Orozco, Perspective on electrostatic interactions of a solute  
622 with a continuum, a direct utilization of ab initio molecular potentials for the prevision  
623 of solvent effects, *Theor. Chem. Acc.* 103 (2000) 343–345.
- 624 [45] P. Politzer, J.S. Murray, in: D.L. Beveridge, R. Lavery, (Eds.), *Theoretical*  
625 *Biochemistry and Molecular Biophysics*, Springer, Berlin, 1991.
- 626 [46] NBO Version 3.1, E.D. Glendening, A.E. Reed, J.E. Carpenter, F. Weinhold.

- 627 [47] C. Adant, M. Dupuis, J.L. Bredas, Ab initio study of the nonlinear optical properties of  
628 urea, electron correlation and dispersion effects, *Int. J. Quantum. Chem.* 56 (1995)  
629 497–507.
- 630 [48] G. Purohit, G.C. Joshi, Second order polarizabilities of some quinolines, *Indian J. Pure*  
631 *Appl. Phys.* 41 (2003) 922–927.
- 632 [49] Y.S. Mary, C.Y. Panicker, H.T. Varghese, K. Raju, T.E. Bolelli, I. Yildiz, C.M.  
633 Granadeiro, H.I.S. Nogueira, Vibrational spectroscopic studies and computational  
634 study of 4-fluoro-N-(2'-hydroxy-4'-nitrophenyl) phenylacetamide, *J. Mol. Struct.* 994  
635 (2011) 223–231.
- 636 [50] S.R. Sheeja, N.A. Mangalam, M.R.P. Kurup, Y.S. Mary, K. Raju, H.T. Varghese, C.Y.  
637 Panicker, Vibrational spectroscopic studies and computational study of quinoline-  
638 2carbaldehyde benzyol hydrazone, *J. Mol. Struct.* 973 (2010) 36–46.
- 639 [51] J.S. Murray, J.M. Seminario, P. Politzer, P. Sjoberg, Average local ionization energies  
640 computed on the surfaces of some strained molecules, *Int. J. Quantum Chem.* 38(S24)  
641 (1990) 645–653.
- 642 [52] P. Politzer, F. Abu-Awwad, J.S. Murray, Comparison of density functional and  
643 Hartree–Fock average local ionization energies on molecular surfaces, *Int. J.*  
644 *Quantum Chem.* 69(4) (1998) 607–613.
- 645 [53] A. Toro-Labb, P. Jaque, J.S. Murray, P. Politzer, Connection between the average  
646 local ionization energy and the Fukui function, *Chem. Phys. Lett.* 407 (2005)  
647 143–146.
- 648 [54] R.G. Parr, Density Functional Theory of Atoms and Molecules, in *Horizons of*  
649 *Quantum Chemistry*, Springer (1980) 5–15.
- 650 [55] A. Michalak, F. De Proft, P. Geerlings, R. Nalewajski, Fukui functions from the  
651 relaxed Kohn-Sham orbitals, *J. Phys. Chem. A* 103 (1999) 762–771.
- 652 [56] X. Ren, Y. Sun, X. Fu, L. Zhu, Z. Cui, DFT comparison of the OH-initiated  
653 degradation mechanisms for five chlorophenoxy herbicides, *J. Mol. Model.* 19 (2013)  
654 2249–2263.
- 655 [57] I. Ai, J.Y. Liu, Mechanism of OH-initiated atmospheric oxidation of E/Z-CF<sub>3</sub>CF=CF<sub>3</sub>:  
656 a quantum mechanical study, *J. Mol. Model.* 20 (2014) 1–10.
- 657 [58] W. Sang-aroon, V. Amornkitbamrung, V. Ruangpornvisuti, A density functional  
658 theory study on peptide bond cleavage at aspartic residues: direct vs cyclic  
659 intermediate hydrolysis, *J. Mol. Model.* 19 (2013) 5501–5513.

- 660 [59] J. Kieffer, É. Brémond, P. Lienard, G. Boccardi, In silico assessment of drug  
661 substances chemical stability, *J. Mol. Struct. THEOCHEM.* 954 (2010) 75–79.
- 662 [60] J.S. Wright, H. Shadnia, L.L. Chepelev, Stability of carbon-centered radicals: Effect  
663 of functional groups on the energetics of addition of molecular oxygen, *J. Comput.*  
664 *Chem.* 30 (2009) 1016–1026.
- 665 [61] P. Lienard, J. Gavartin, G. Boccardi, M. Meunier, Predicting drug substances  
666 autoxidation, *Pharm. Res.* 32 (2015) 300–310.
- 667 [62] T. Andersson, A. Broo, E. Evertsson, Prediction of Drug Candidates' Sensitivity  
668 Toward Autoxidation: Computational Estimation of C-H Dissociation Energies of  
669 Carbon-centered Radicals, *J. Pharm. Sci.* 103 (7) (2014) 1949–1955.
- 670 [63] R.V. Vaz, J.R. Gomes, C.M. Silva, Molecular dynamics simulation of diffusion  
671 coefficients and structural properties of ketones in supercritical CO<sub>2</sub> at infinite  
672 dilution, *J. Supercritic. Fluids*, 107 (2016) 630–638.
- 673 [64] M. Cunha-Rodrigues, M. Prudencio, M.M. Mota, W. Haas, Antimalarial drugs–host  
674 targets (re)visited, *Biotechnol. J.* 1 (2006) 321–332.
- 675 [65] C. Daneshvar, T.M. Davis, J. Cox-Singh, M.Z. Rafa'ee, S.K. Zakaria, P.C. Divis, B.  
676 Singh, Clinical and laboratory features of human Plasmodium knowlesi infection, *Clin.*  
677 *Infect. Dis.* 49 (2009) 852–860.
- 678 [66] B. Gunsaru, S.J. Burgess, W. Morrill, J.X. Kelly, S. Shomloo, M.J. Smilkstein, K.  
679 Liebman, D.H. Peyton, Simplified reversed chloroquines to overcome malaria resistance  
680 to quinoline-based drugs, *Antimicrob. Agents Chemother.* 61 (2017) 1913–1916.
- 681 [67] B. Sandhya, S. Kumar, S. Drabu, R. Kumar, Structural modifications of quinoline-  
682 based antimalarial agents: Recent developments, *J. Pharm. Bioallied. Sci.* 2 (2010)  
683 64–71.
- 684 [68] A. Lagunin, A. Stepanchikova, D. Filimonov, V. Poroikov, PASS: prediction of activity  
685 spectra for biologically active substances, *Bioinformatics* 16 (2000) 747–748.
- 686 [69] A.C.R. Sodero, B. Abraham-Vieira, P.H.M. Torres, P.G. Pascutti, C.R.S. Garcia, V.F.  
687 Ferreira, D.R. da Rocha, S.B. Ferreira, F.P. Silva, Atovaquone is a drug that inhibits  
688 the respiratory chain of Plasmodium falciparum, but with serious limitations like known  
689 resistance, low bioavailability and high plasma protein binding, *Mem. Inst. Oswaldo.*  
690 *Cruz*, 112 (2017) 299–308.

- 691 [70] A.M. Stickles, L.M. Ting, J.M. Morrissey, Y. Li, M.W. Mather, E. Meermeier, A.M.  
692 Pershing, I.P. Forquer, G.P. Miley, S. Pou, R.W. Winter, D.J. Hinrichs, J.X. Kelly, K.  
693 Kim, A.B. Vaidya, M.K. Riscoe, A. Nilsen, Inhibition of Cytochrome bc1 as a Strategy  
694 for Single-Dose, Multi-Stage Antimalarial Therapy, *Am. J. Trop. Med. Hyg.* 92 (2015)  
695 1195–1201.
- 696 [71] G.M. Morris, R. Huey, W. Lindstrom, M.F. Sanner, R.K. Belew, D.S. Goodsell, A.J.  
697 Olson, Autodock4 and AutoDockTools4: automated docking with selective receptor  
698 flexibility, *J. Comput. Chem.* 16 (2009) 2785–2791.
- 699 [72] O. Trott, A.J. Olson, AutoDock Vina: Improving the speed and accuracy of docking  
700 with a new scoring function, efficient optimization and multithreading, *J. Comput.*  
701 *Chem.* 31 (2010) 455–461.
- 702 [73] J.A. War, K. Jalaja, Y.S. Mary, C.Y. Panicker, S. Armakovic, S.J. Armakovic, S.K.  
703 Srivastava, C. Van Alsenoy, Spectroscopic characterization of 1-[3-(1H-imidazol-1-  
704 yl)propyl]-3-phenylthiourea and assessment of reactive and optoelectronic properties  
705 employing DFT calculations and molecular dynamics simulations, *J. Mol. Struct.* 1129  
706 (2017) 72–85.
- 707 [74] I. Çapan, S. Servi, I. Yıldırım, Y. Sert, Synthesis, DFT Study, Molecular Docking and  
708 Drug Likeness Analysis of the New Hydrazine-1-Carbothioamide, Triazole and  
709 Thiadiazole Derivatives: Potential Inhibitors of HSP90, *ChemistrySelect* 6 (2021)  
710 5838–5846.
- 711 [75] C.A. Lipinski, F. Lombardo, B.W. Dominy P.J. Feeney, Experimental and  
712 computational approaches to estimate solubility and permeability in drug discovery and  
713 development settings, *Adv Drug Deliv. Rev.* 23 (1997) 3–25.

714

## 715 **Figure Caption**

716

717 Fig 1 FT-IR

718 Fig 2 FT-Raman

719 Fig 3 Molecule

720 Fig 4A HOMO-LUMO -1

721 Fig 4B HOMO-LUMO-2

722 Fig 4C HOMO-LUMO-3

723 Fig 4D HOMO-LUMO-4

724 Fig 5A MEP-1

725 Fig 5B MEP-2

726 Fig 5C MEP-3

727 Fig 5D MEP-4

728 Fig 6 ALIE

729 Fig 7 Fukui

730 Fig 8 BDE

731 Fig 9 RDF

732 Fig 10 Docking-1

733 Fig 11 Docking-2

734 Fig 12 Docking-3

735 Fig 13 Bioavailability

736

737 **Table Caption**

738

739 Table 1 Geometrical Parameters

740 Table 2 Frequency

741 Table 3 HOMO-LUMO

742 Table 4 NBO-1

743 Table 5 NBO-2

744 Table 6 NLO of Substitution

745 Table 7 Solubility parameter

746 Table 8 Pass Analysis



747 Table 9 Docking

748 Table 10 Drug-Likeness





## Highlights

- \* The quinoline derivative was synthesized and FT-IR and FT-Raman spectra were measured
- \* DFT calculations were performed
- \* Most reactive sites were identified
- \* Results of halogen substitution in the calculations of chemical descriptors and HOMO-LUMO gap were calculated.
- \* Molecular docking studies between the title compound and 4PD4 protein were performed.




**Scheme 1.** Preparation of the target compound: (a) microwave irradiation





**Fig. 1. FT-IR spectrum of CPCHODQ6C**



**Fig. 2. FT-Raman spectrum of CPCHODQ6C**




Fig. 3. Optimized geometry of CPCHODQ6C




Fig. 4A. HOMO-LUMO plots of CPCHODQ6C with Fluorine substitution







Fig. 4B. HOMO-LUMO plots of CPCHODQ6C with Chlorine substitution




**Fig. 4C. HOMO-LUMO plots of CPCHODQ6C with Bromine substitution**



**Fig. 4D. HOMO-LUMO plots of CPCHODQ6C**




**Fig. 5A. MEP plots of CPCHODQ6C with Fluorine substitution**




**Fig. 5B. MEP plots of CPCHODQ6C with Chlorine substitution**





**Fig. 5C. MEP plots of CPCHODQ6C with Bromine substitution**



**Fig. 5D. MEP plot of CPCHODQ6C**

# ALIE




Fig. 6. ALIE surface of CPCHODQ6C







Fig. 7. Fukui functions a)  $f^+$  and b)  $f^-$  of the CPCHODQ6C




**Fig. 8. BDEs of all single acyclic bonds of CPCHODQ6C**




**Fig. 9. RDFs of CPCHODQ6C atoms with significant interactions with water molecules**




**Fig. 10. Interactive plots of amino acids of the receptor with the ligand**



**Fig. 11. The docked ligand of CPCHODQ6C at the active site of receptor**



**Fig. 12.** The docked ligand embedded in the catalytic site of cytochrome BC1 complex



**Fig. 13.** The bioavailability radar of CPCHODQ6C



**Table 1**

Optimized Geometrical parameters of 3-[(4-carboxyphenyl) carbamoyl] -4-hydroxy-2-oxo-1, 2-dihydroquinoline-6-carboxylic acid.

Bond length (Å)		Bond angle (°)		Dihedral angle (°)	
C <sub>1</sub> -C <sub>2</sub>	1.3824	C <sub>2</sub> -C <sub>1</sub> -C <sub>6</sub>	120.9	C <sub>6</sub> -C <sub>1</sub> -C <sub>2</sub> -C <sub>3</sub>	-0.0
C <sub>1</sub> -C <sub>6</sub>	1.4113	C <sub>2</sub> -C <sub>1</sub> -H <sub>7</sub>	120.8	C <sub>2</sub> -C <sub>1</sub> -C <sub>6</sub> -C <sub>5</sub>	-0.0
C <sub>1</sub> -H <sub>7</sub>	1.0863	C <sub>1</sub> -C <sub>2</sub> -C <sub>3</sub>	119.6	C <sub>2</sub> -C <sub>1</sub> -C <sub>6</sub> -C <sub>35</sub>	180.0
C <sub>2</sub> -C <sub>3</sub>	1.4084	C <sub>1</sub> -C <sub>2</sub> -H <sub>8</sub>	120.7	C <sub>1</sub> -C <sub>2</sub> -C <sub>3</sub> -C <sub>4</sub>	0.0
C <sub>2</sub> -H <sub>8</sub>	1.0880	C <sub>6</sub> -C <sub>1</sub> -H <sub>7</sub>	118.3	C <sub>1</sub> -C <sub>2</sub> -C <sub>3</sub> -N <sub>10</sub>	180.0
C <sub>3</sub> -C <sub>4</sub>	1.4130	C <sub>1</sub> -C <sub>6</sub> -C <sub>5</sub>	119.6	C <sub>2</sub> -C <sub>3</sub> -C <sub>4</sub> -C <sub>5</sub>	0.0
C <sub>3</sub> -N <sub>10</sub>	1.3745	C <sub>1</sub> -C <sub>6</sub> -C <sub>35</sub>	117.8	C <sub>2</sub> -C <sub>3</sub> -C <sub>4</sub> -C <sub>13</sub>	-180.0
C <sub>4</sub> -C <sub>5</sub>	1.4045	C <sub>3</sub> -C <sub>2</sub> -H <sub>8</sub>	119.7	N <sub>10</sub> -C <sub>3</sub> -C <sub>4</sub> -C <sub>5</sub>	-180.0
C <sub>4</sub> -C <sub>13</sub>	1.4498	C <sub>2</sub> -C <sub>3</sub> -C <sub>4</sub>	120.1	N <sub>10</sub> -C <sub>3</sub> -C <sub>4</sub> -C <sub>13</sub>	0.0
C <sub>5</sub> -C <sub>6</sub>	1.3916	C <sub>2</sub> -C <sub>3</sub> -N <sub>10</sub>	121.3	C <sub>2</sub> -C <sub>3</sub> -N <sub>10</sub> -C <sub>12</sub>	-180.0
C <sub>5</sub> -H <sub>9</sub>	1.0841	C <sub>4</sub> -C <sub>3</sub> -N <sub>10</sub>	118.6	C <sub>4</sub> -C <sub>3</sub> -N <sub>10</sub> -C <sub>12</sub>	0.0
C <sub>6</sub> -C <sub>35</sub>	1.4849	C <sub>3</sub> -C <sub>4</sub> -C <sub>5</sub>	119.5	C <sub>3</sub> -C <sub>4</sub> -C <sub>5</sub> -C <sub>6</sub>	-0.0
N <sub>10</sub> -H <sub>11</sub>	1.0127	C <sub>3</sub> -C <sub>4</sub> -C <sub>13</sub>	118.4	C <sub>13</sub> -C <sub>4</sub> -C <sub>5</sub> -C <sub>6</sub>	180.0
N <sub>10</sub> -C <sub>12</sub>	1.3914	C <sub>3</sub> -N <sub>10</sub> -H <sub>11</sub>	119.9	C <sub>3</sub> -C <sub>4</sub> -C <sub>13</sub> -C <sub>14</sub>	-0.0
C <sub>12</sub> -C <sub>14</sub>	1.4579	C <sub>3</sub> -N <sub>10</sub> -C <sub>12</sub>	126.0	C <sub>3</sub> -C <sub>4</sub> -C <sub>13</sub> -O <sub>15</sub>	-180.0
C <sub>12</sub> -O <sub>16</sub>	1.2374	C <sub>5</sub> -C <sub>4</sub> -C <sub>13</sub>	122.1	C <sub>5</sub> -C <sub>4</sub> -C <sub>13</sub> -C <sub>14</sub>	180.0
C <sub>13</sub> -C <sub>14</sub>	1.3989	C <sub>4</sub> -C <sub>5</sub> -C <sub>6</sub>	120.3	C <sub>5</sub> -C <sub>4</sub> -C <sub>13</sub> -O <sub>15</sub>	-0.0
C <sub>13</sub> -O <sub>15</sub>	1.3198	C <sub>4</sub> -C <sub>5</sub> -H <sub>9</sub>	119.0	C <sub>4</sub> -C <sub>5</sub> -C <sub>6</sub> -C <sub>1</sub>	0.0
C <sub>14</sub> -C <sub>18</sub>	1.4854	C <sub>4</sub> -C <sub>13</sub> -C <sub>14</sub>	121.2	C <sub>4</sub> -C <sub>5</sub> -C <sub>6</sub> -C <sub>35</sub>	-180.0
O <sub>15</sub> -H <sub>17</sub>	1.0122	C <sub>4</sub> -C <sub>13</sub> -O <sub>15</sub>	115.9	C <sub>1</sub> -C <sub>6</sub> -C <sub>35</sub> -O <sub>36</sub>	0.0
O <sub>16</sub> -H <sub>39</sub>	1.7992	C <sub>6</sub> -C <sub>5</sub> -H <sub>9</sub>	120.7	C <sub>1</sub> -C <sub>6</sub> -C <sub>35</sub> -O <sub>37</sub>	180.0
H <sub>17</sub> -O <sub>19</sub>	1.5785	C <sub>5</sub> -C <sub>6</sub> -C <sub>35</sub>	122.5	C <sub>5</sub> -C <sub>6</sub> -C <sub>35</sub> -O <sub>36</sub>	-180.0
C <sub>18</sub> -O <sub>19</sub>	1.2507	C <sub>6</sub> -C <sub>35</sub> -O <sub>36</sub>	124.7	C <sub>5</sub> -C <sub>6</sub> -C <sub>35</sub> -O <sub>37</sub>	-0.0
C <sub>18</sub> -N <sub>20</sub>	1.3596	C <sub>6</sub> -C <sub>35</sub> -O <sub>37</sub>	113.0	C <sub>3</sub> -N <sub>10</sub> -C <sub>12</sub> -C <sub>14</sub>	-0.0
N <sub>20</sub> -C <sub>21</sub>	1.4047	H <sub>11</sub> -N <sub>10</sub> -C <sub>12</sub>	114.0	C <sub>3</sub> -N <sub>10</sub> -C <sub>12</sub> -O <sub>16</sub>	180.0
N <sub>20</sub> -H <sub>39</sub>	1.0244	N <sub>10</sub> -C <sub>12</sub> -C <sub>14</sub>	116.0	N <sub>10</sub> -C <sub>12</sub> -C <sub>14</sub> -C <sub>13</sub>	0.0
C <sub>21</sub> -C <sub>22</sub>	1.4068	N <sub>10</sub> -C <sub>12</sub> -O <sub>16</sub>	118.0	N <sub>10</sub> -C <sub>12</sub> -C <sub>14</sub> -C <sub>18</sub>	180.0
C <sub>21</sub> -C <sub>23</sub>	1.4092	C <sub>14</sub> -C <sub>12</sub> -O <sub>16</sub>	126.0	O <sub>16</sub> -C <sub>12</sub> -C <sub>14</sub> -C <sub>13</sub>	-180.0
C <sub>22</sub> -C <sub>24</sub>	1.3924	C <sub>12</sub> -C <sub>14</sub> -C <sub>13</sub>	119.8	O <sub>16</sub> -C <sub>12</sub> -C <sub>14</sub> -C <sub>18</sub>	0.0
C <sub>22</sub> -H <sub>25</sub>	1.0814	C <sub>12</sub> -C <sub>14</sub> -C <sub>18</sub>	122.1	C <sub>4</sub> -C <sub>13</sub> -C <sub>14</sub> -C <sub>12</sub>	-0.0
C <sub>23</sub> -C <sub>26</sub>	1.3864	C <sub>12</sub> -C <sub>16</sub> -H <sub>39</sub>	99.6	C <sub>4</sub> -C <sub>13</sub> -C <sub>14</sub> -C <sub>18</sub>	-180.0
C <sub>23</sub> -H <sub>27</sub>	1.0896	C <sub>14</sub> -C <sub>13</sub> -O <sub>15</sub>	123.0	O <sub>15</sub> -C <sub>13</sub> -C <sub>14</sub> -C <sub>12</sub>	180.0
C <sub>24</sub> -C <sub>28</sub>	1.4017	C <sub>13</sub> -C <sub>14</sub> -C <sub>18</sub>	118.1	O <sub>15</sub> -C <sub>13</sub> -C <sub>14</sub> -C <sub>18</sub>	0.0
C <sub>24</sub> -H <sub>29</sub>	1.0859	C <sub>13</sub> -O <sub>15</sub> -H <sub>17</sub>	106.1	C <sub>12</sub> -C <sub>14</sub> -C <sub>18</sub> -O <sub>19</sub>	180.0
C <sub>26</sub> -C <sub>28</sub>	1.4030	C <sub>14</sub> -C <sub>18</sub> -O <sub>19</sub>	120.2	C <sub>12</sub> -C <sub>14</sub> -C <sub>18</sub> -N <sub>20</sub>	0.0
C <sub>26</sub> -H <sub>30</sub>	1.0863	C <sub>14</sub> -C <sub>18</sub> -N <sub>20</sub>	116.8	C <sub>13</sub> -C <sub>14</sub> -C <sub>18</sub> -O <sub>19</sub>	0.0
C <sub>28</sub> -C <sub>31</sub>	1.4815	O <sub>15</sub> -H <sub>17</sub> -O <sub>19</sub>	149.6	C <sub>13</sub> -C <sub>14</sub> -C <sub>18</sub> -N <sub>20</sub>	180.0
C <sub>31</sub> -O <sub>32</sub>	1.2132	O <sub>19</sub> -C <sub>18</sub> -N <sub>20</sub>	123.0	C <sub>14</sub> -C <sub>18</sub> -N <sub>20</sub> -C <sub>21</sub>	-180.0
C <sub>31</sub> -O <sub>33</sub>	1.3596	C <sub>18</sub> -O <sub>19</sub> -H <sub>17</sub>	103.1	O <sub>19</sub> -C <sub>18</sub> -N <sub>20</sub> -C <sub>21</sub>	0.0
O <sub>33</sub> -H <sub>34</sub>	0.9720	C <sub>18</sub> -N <sub>20</sub> -C <sub>21</sub>	129.2	C <sub>18</sub> -N <sub>20</sub> -C <sub>21</sub> -C <sub>22</sub>	-0.0
C <sub>35</sub> -O <sub>36</sub>	1.2120	C <sub>18</sub> -N <sub>20</sub> -H <sub>39</sub>	113.5	C <sub>18</sub> -N <sub>20</sub> -C <sub>21</sub> -C <sub>23</sub>	180.0
C <sub>35</sub> -O <sub>37</sub>	1.3554	C <sub>21</sub> -N <sub>20</sub> -H <sub>39</sub>	117.3	N <sub>20</sub> -C <sub>21</sub> -C <sub>22</sub> -C <sub>24</sub>	-180.0
O <sub>37</sub> -H <sub>38</sub>	0.9722	N <sub>20</sub> -C <sub>21</sub> -C <sub>22</sub>	124.3	C <sub>23</sub> -C <sub>21</sub> -C <sub>22</sub> -C <sub>24</sub>	0.0
		N <sub>20</sub> -C <sub>21</sub> -C <sub>23</sub>	116.3	N <sub>20</sub> -C <sub>21</sub> -C <sub>23</sub> -C <sub>26</sub>	180.0

		N <sub>20</sub> -H <sub>39</sub> -O <sub>16</sub>	141.9	C <sub>22</sub> -C <sub>21</sub> -C <sub>23</sub> -C <sub>26</sub>	-0.0
		C <sub>22</sub> -C <sub>21</sub> -C <sub>23</sub>	119.4	C <sub>21</sub> -C <sub>22</sub> -C <sub>24</sub> -C <sub>28</sub>	0.0
		C <sub>21</sub> -C <sub>22</sub> -C <sub>24</sub>	119.5	C <sub>21</sub> -C <sub>23</sub> -C <sub>26</sub> -C <sub>28</sub>	0.0
		C <sub>21</sub> -C <sub>22</sub> -H <sub>25</sub>	119.7	C <sub>22</sub> -C <sub>24</sub> -C <sub>28</sub> -C <sub>26</sub>	-0.0
		C <sub>21</sub> -C <sub>23</sub> -C <sub>26</sub>	120.5	C <sub>22</sub> -C <sub>24</sub> -C <sub>28</sub> -C <sub>31</sub>	180.0
		C <sub>21</sub> -C <sub>23</sub> -H <sub>27</sub>	119.5	C <sub>23</sub> -C <sub>26</sub> -C <sub>28</sub> -C <sub>24</sub>	0.0
		C <sub>24</sub> -C <sub>22</sub> -H <sub>25</sub>	120.8	C <sub>23</sub> -C <sub>26</sub> -C <sub>28</sub> -C <sub>31</sub>	-180.0
		C <sub>22</sub> -C <sub>24</sub> -C <sub>28</sub>	121.2	C <sub>24</sub> -C <sub>28</sub> -C <sub>31</sub> -O <sub>32</sub>	180.0
		C <sub>22</sub> -C <sub>24</sub> -H <sub>29</sub>	119.4	C <sub>24</sub> -C <sub>28</sub> -C <sub>31</sub> -O <sub>33</sub>	-0.0
		C <sub>26</sub> -C <sub>23</sub> -H <sub>27</sub>	120.0	C <sub>26</sub> -C <sub>28</sub> -C <sub>31</sub> -O <sub>32</sub>	0.0
		C <sub>23</sub> -C <sub>26</sub> -C <sub>28</sub>	120.4	C <sub>26</sub> -C <sub>28</sub> -C <sub>31</sub> -O <sub>33</sub>	180.0
		C <sub>23</sub> -C <sub>26</sub> -H <sub>30</sub>	120.8		
		C <sub>28</sub> -C <sub>24</sub> -H <sub>29</sub>	119.5		
		C <sub>24</sub> -C <sub>28</sub> -C <sub>26</sub>	119.1		
		C <sub>24</sub> -C <sub>28</sub> -C <sub>31</sub>	122.8		
		C <sub>28</sub> -C <sub>26</sub> -H <sub>30</sub>	118.8		
		C <sub>26</sub> -C <sub>28</sub> -C <sub>31</sub>	118.2		
		C <sub>28</sub> -C <sub>31</sub> -O <sub>32</sub>	125.2		
		C <sub>28</sub> -C <sub>31</sub> -O <sub>33</sub>	113.1		
		O <sub>32</sub> -C <sub>31</sub> -O <sub>33</sub>	121.7		
		C <sub>31</sub> -O <sub>33</sub> -H <sub>34</sub>	105.8		
		O <sub>36</sub> -C <sub>35</sub> -O <sub>37</sub>	122.3		
		C <sub>35</sub> -O <sub>37</sub> -H <sub>38</sub>	106.2		

**Table 3**

HOMO, LUMO and Chemical descriptors of CPCHODQ6C with halogen substitutions

	$E_{\text{HOMO}}(\text{LBS})$	$E_{\text{LUMO}}(\text{LBS})$	$I = -E_{\text{HOMO}}$	$A = -E_{\text{LUMO}}$	Gap	$\eta$	$\mu$	$\omega$
CPCHODQ6C	-8.482	-5.325	8.540	5.894	2.646	1.323	-7.217	19.684
7F	-8.423	-5.172	8.481	5.730	2.751	1.376	-7.106	18.349
8F	-8.276	-5.182	8.334	5.741	2.593	1.297	-7.038	19.095
9F	-8.404	-5.151	8.462	5.708	2.754	1.377	-7.085	18.227
7Cl	-8.105	-5.176	8.163	5.734	2.429	1.215	-6.949	19.872
8Cl	-7.885	-4.622	7.943	5.140	2.803	1.402	-6.542	15.263
9Cl	-8.039	-5.140	8.097	5.696	2.401	1.205	-6.897	19.738
7Br	-8.461	-5.288	8.519	5.854	2.665	1.333	-7.187	19.375
8Br	-8.484	-5.298	8.542	5.865	2.677	1.339	-7.196	19.336
9Br	-8.427	-5.283	8.485	5.849	2.636	1.318	-7.167	19.486

LBS=Larger Basis Set



**Table 4**

NBO result showing the formation of Lewis and non-Lewis orbitals

Bond (A-B)	ED/Energy	EDA%	EDB%	NBO	S%	P%
$\sigma_{C_1-C_2}$	0.98856	49.65	50.35	0.7046(sp <sup>1.79</sup> )C	35.80	64.20
-	-0.73127	-	-	+0.7096(sp <sup>1.75</sup> )C	36.32	63.68
$\pi_{C_1-C_2}$	0.84908	45.37	54.63	0.6736(sp <sup>1.00</sup> )C	0.00	100.0
-	-0.28780	-	-	+0.7391(sp <sup>1.00</sup> )C	0.00	100.0
$\sigma_{C_1-C_6}$	0.98652	49.22	50.78	0.7016(sp <sup>1.88</sup> )C	34.78	65.22
-	-0.71144	-	-	+0.7126(sp <sup>1.93</sup> )C	34.11	65.89
$\sigma_{C_2-C_3}$	0.98554	48.51	51.49	0.6965(sp <sup>1.90</sup> )C	34.43	65.57
-	-0.73032	-	-	+0.7176(sp <sup>1.77</sup> )C	36.06	63.94
$\sigma_{C_3-C_4}$	0.98180	49.95	50.05	0.7068(sp <sup>1.81</sup> )C	35.65	64.35
-	-0.72658	-	-	+0.7074(sp <sup>2.04</sup> )C	32.91	67.09
$\sigma_{C_3-N_{10}}$	0.99237	38.03	61.97	0.6167(sp <sup>2.55</sup> )C	28.14	71.86
-	-0.85958	-	-	+0.7872(sp <sup>1.62</sup> )N	38.17	61.83
$\sigma_{C_4-C_5}$	0.98465	51.42	48.58	0.7171(sp <sup>1.84</sup> )C	35.15	64.85
-	-0.71830	-	-	+0.6970(sp <sup>1.88</sup> )C	34.72	65.28
$\sigma_{C_4-C_{13}}$	0.98382	50.54	49.46	0.7109(sp <sup>2.13</sup> )C	31.90	68.10
-	-0.71446	-	-	+0.7033(sp <sup>1.82</sup> )C	35.45	64.55
$\sigma_{C_5-C_6}$	0.98730	49.44	50.56	0.7031(sp <sup>1.82</sup> )C	35.41	64.59
-	-0.72601	-	-	+0.7110(sp <sup>1.79</sup> )C	35.88	64.12
$\pi_{C_5-C_6}$	0.82480	42.74	57.26	0.6538(sp <sup>1.00</sup> )C	0.00	100.0
-	-0.28108	-	-	+0.7567(sp <sup>1.00</sup> )C	0.00	100.0
$\sigma_{C_6-C_{35}}$	0.98528	51.82	48.18	0.7199(sp <sup>2.34</sup> )C	29.96	70.04
-	-0.70075	-	-	+0.6941(sp <sup>1.49</sup> )C	40.15	59.85
$\sigma_{N_{10}-C_{12}}$	0.99174	63.95	36.05	0.7997(sp <sup>1.85</sup> )N	35.15	64.85
-	-0.82886	-	-	+0.6004(sp <sup>2.44</sup> )C	29.03	70.97
$\sigma_{C_{12}-C_{14}}$	0.98436	48.15	51.85	0.6939(sp <sup>1.62</sup> )C	38.21	61.79
-	-0.70828	-	-	+0.7201(sp <sup>2.03</sup> )C	33.05	66.95
$\sigma_{C_{12}-O_{16}}$	0.99437	35.12	64.88	0.5926(sp <sup>2.05</sup> )C	32.83	67.17
-	-1.01364	-	-	+0.8055(sp <sup>1.87</sup> )O	34.90	65.10
$\pi_{C_{12}-O_{16}}$	0.98730	30.20	69.80	0.5495(sp <sup>99.99</sup> )C	0.00	100.0
-	-0.37506	-	-	+0.8355(sp <sup>1.00</sup> )O	0.01	99.99
$\sigma_{C_{13}-C_{14}}$	0.98751	49.53	50.47	0.7038(sp <sup>1.63</sup> )C	38.09	61.95
-	-0.75255	-	-	+0.7104(sp <sup>1.87</sup> )C	34.88	65.12
$\pi_{C_{13}-C_{14}}$	0.84461	38.75	61.25	0.6225(sp <sup>1.00</sup> )C	0.00	100.0
-	-0.29939	-	-	+0.7826(sp <sup>1.00</sup> )C	0.00	100.0
$\sigma_{C_{13}-O_{15}}$	0.99445	33.10	66.90	0.5753(sp <sup>2.78</sup> )C	26.48	73.52
-	-0.93982	-	-	+0.8179(sp <sup>2.30</sup> )O	30.31	69.69
$\sigma_{C_{14}-C_{18}}$	0.98111	51.18	48.82	0.7154(sp <sup>2.12</sup> )C	32.04	67.96
-	-0.70381	-	-	+0.6987(sp <sup>1.66</sup> )C	37.58	62.42
$\sigma_{C_{18}-O_{19}}$	0.99269	32.35	67.65	0.5688(sp <sup>2.33</sup> )C	30.05	69.95
-	-0.82174	-	-	+0.8225(sp <sup>2.08</sup> )O	32.43	67.57
$\pi_{C_{18}-O_{19}}$	0.97381	31.11	68.89	0.5577(sp <sup>99.99</sup> )C	0.42	99.58
-	-0.53501	-	-	+0.8300(sp <sup>99.99</sup> )O	0.79	99.21
$\sigma_{C_{18}-N_{20}}$	0.99039	40.13	59.87	0.6335(sp <sup>2.12</sup> )C	32.03	67.97
-	-0.83505	-	-	+0.7737(sp <sup>1.95</sup> )N	33.85	66.15
$\sigma_{N_{20}-C_{21}}$	0.98948	59.54	40.46	0.7716(sp <sup>1.61</sup> )N	38.38	61.26
-	-0.85498	-	-	+0.6361(sp <sup>2.36</sup> )C	29.73	70.27

$\sigma_{C_{21}-C_{22}}$	0.98732	51.04	48.96	0.7144(sp <sup>1.81</sup> )C	35.65	64.35
-	-0.70552	-	-	+0.6997(sp <sup>1.96</sup> )C	33.78	66.22
$\sigma_{C_{21}-C_{23}}$	0.98568	51.52	48.48	0.7177(sp <sup>1.90</sup> )C	34.54	65.46
-	-0.69940	-	-	+0.6963(sp <sup>1.94</sup> )C	34.03	65.97
$\sigma_{C_{22}-C_{24}}$	0.98909	49.60	50.40	0.7042(sp <sup>1.74</sup> )C	36.46	63.54
-	-0.72682	-	-	+0.7100(sp <sup>1.79</sup> )C	35.81	64.19
$\pi_{C_{22}-C_{24}}$	0.82033	40.71	59.29	0.6380(sp <sup>1.00</sup> )C	0.00	0.00
-	-0.27619	-	-	+0.7700(sp <sup>1.00</sup> )C	100.0	100.0
$\sigma_{C_{23}-C_{26}}$	0.98969	49.40	50.60	0.7029(sp <sup>1.76</sup> )C	36.19	63.81
-	-0.72456	-	-	+0.7113(sp <sup>1.80</sup> )C	35.75	64.25
$\pi_{C_{23}-C_{26}}$	0.80982	39.89	60.11	0.6316(sp <sup>1.00</sup> )C	0.00	0.00
-	-0.27298	-	-	+0.7753(sp <sup>1.00</sup> )C	100.0	100.0
$\sigma_{C_{24}-C_{28}}$	0.98827	49.44	50.56	0.7031(sp <sup>1.91</sup> )C	34.37	65.63
-	-0.71450	-	-	+0.7110(sp <sup>1.82</sup> )C	35.50	64.50
$\sigma_{C_{26}-C_{28}}$	0.98708	49.41	50.59	0.7029(sp <sup>1.91</sup> )C	34.36	65.64
-	-0.71181	-	-	+0.7112(sp <sup>1.88</sup> )C	34.75	65.25
$\sigma_{C_{28}-C_{31}}$	0.98597	51.28	48.72	0.7161(sp <sup>2.37</sup> )C	29.71	70.29
-	-0.70258	-	-	+0.6980(sp <sup>1.50</sup> )C	39.97	60.03
$\sigma_{C_{31}-O_{32}}$	0.99631	34.18	65.82	0.5373(sp <sup>1.98</sup> )C	0.00	100.0
-	-1.05946	-	-	+0.8434(sp <sup>1.80</sup> )O	0.00	100.0
$\pi_{C_{31}-O_{32}}$	0.98183	33.53	66.74	0.5847(sp <sup>1.00</sup> )C	0.00	100.0
-	-0.39740	-	-	+0.8113(sp <sup>1.00</sup> )O	0.00	100.0
$\sigma_{C_{31}-O_{33}}$	0.99564	30.75	69.25	0.5547(sp <sup>2.78</sup> )C	26.48	73.52
-	-0.92044	-	-	+0.8321(sp <sup>2.17</sup> )O	31.57	68.43
$\sigma_{C_{35}-O_{36}}$	0.99620	34.08	65.92	0.5838(sp <sup>1.98</sup> )C	33.57	66.43
-	-1.05599	-	-	+0.8119(sp <sup>1.80</sup> )O	35.70	64.30
$\pi_{C_{35}-O_{36}}$	0.98967	30.73	69.27	0.5543(sp <sup>1.00</sup> )C	0.00	100.0
-	-0.39675	-	-	+0.8323(sp <sup>1.00</sup> )O	0.00	100.0
$\sigma_{C_{35}-O_{37}}$	0.99554	30.77	69.23	0.5547(sp <sup>2.79</sup> )C	26.41	73.59
-	-0.91820	-	-	+0.8321(sp <sup>2.16</sup> )O	31.66	68.34
$n_1N_{10}$	0.81511	-	-	sp <sup>99.99</sup>	0.03	99.97
-	-0.29998	-	-	-	-	-
$n_1O_{15}$	0.98581	-	-	sp <sup>1.44</sup>	41.23	58.77
-	-0.57445	-	-	-	-	-
$n_2O_{15}$	0.88442	-	-	sp <sup>99.99</sup>	0.01	99.99
-	-0.33551	-	-	-	-	-
$n_3O_{15}$	0.80785	-	-	sp <sup>2.49</sup>	28.33	71.67
-	-0.54637	-	-	-	-	-
$n_1O_{16}$	0.98710	-	-	sp <sup>0.54</sup>	64.66	35.34
-	-0.69479	-	-	-	-	-
$n_2O_{16}$	0.91141	-	-	sp <sup>99.99</sup>	0.42	99.58
-	-0.26540	-	-	-	-	-
$n_1O_{19}$	0.98252	-	-	sp <sup>0.82</sup>	55.06	44.94
-	-0.64215	-	-	-	-	-
$n_2O_{19}$	0.91962	-	-	sp <sup>6.35</sup>	13.60	86.40
-	-0.39219	-	-	-	-	-
$n_1N_{20}$	0.86698	-	-	sp <sup>2.76</sup>	26.62	73.38
-	-0.33229	-	-	-	-	-

n <sub>1</sub> O <sub>32</sub>	0.98829	-	-	sp <sup>0.55</sup>	64.35	35.65
-	-0.71587	-	-	-	-	-
n <sub>2</sub> O <sub>32</sub>	0.93126	-	-	sp <sup>1.00</sup>	0.01	99.99
-	-0.29119	-	-	-	-	-
n <sub>1</sub> O <sub>33</sub>	0.98979	-	-	sp <sup>1.15</sup>	46.43	53.57
-	-0.61362	-	-	-	-	-
n <sub>2</sub> O <sub>33</sub>	0.91343	-	-	sp <sup>1.00</sup>	0.00	100.0
-	-0.35262	-	-	-	-	-
n <sub>1</sub> O <sub>36</sub>	0.98819	-	-	sp <sup>0.55</sup>	64.33	35.67
-	-0.71428	-	-	-	-	-
n <sub>2</sub> O <sub>36</sub>	0.93154	-	-	sp <sup>1.00</sup>	0.01	99.99
-	-0.28884	-	-	-	-	-
n <sub>1</sub> O <sub>37</sub>	0.98969	-	-	sp <sup>1.16</sup>	46.37	53.63
-	-0.60952	-	-	-	-	-
n <sub>2</sub> O <sub>37</sub>	0.91664	-	-	sp <sup>1.00</sup>	0.00	100.0
-	-0.34980	-	-	-	-	-

**Table 5**

Second-order perturbation theory analysis of Fock matrix in NBO basis corresponding to the intra molecular bonds of CPCHODQ6C

Donor(i)	type	ED/e	Acceptor(j)	Type	ED/e	E(2) <sup>a</sup>	E(j)-E(i) <sup>b</sup>	F(ij) <sup>c</sup>
C <sub>5</sub> -C <sub>6</sub>	$\sigma$	0.98733	C <sub>35</sub> -O <sub>36</sub>	$\sigma^*$	0.13399	1.25	1.20	0.049
-	$\pi$	0.82446	C <sub>35</sub> -O <sub>36</sub>	$\pi^*$	0.13399	14.41	0.24	0.076
-	$\pi$	-	C <sub>1</sub> -C <sub>2</sub>	$\pi^*$	0.12995	11.73	0.28	0.074
C <sub>13</sub> -C <sub>14</sub>	$\sigma$	0.98754	C <sub>4</sub> -C <sub>5</sub>	$\sigma^*$	0.01001	1.84	1.26	0.061
-	$\sigma$	-	C <sub>18</sub> -N <sub>20</sub>	$\sigma^*$	0.02628	1.55	1.16	0.054
-	$\pi$	0.84525	C <sub>12</sub> -O <sub>16</sub>	$\pi^*$	0.00515	16.45	0.26	0.084
-	$\pi$	-	C <sub>18</sub> -O <sub>19</sub>	$\pi^*$	0.13952	16.22	0.25	0.082
LPC <sub>4</sub>	$\sigma$	0.54382	C <sub>5</sub> -C <sub>6</sub>	$\pi^*$	0.15882	35.28	0.15	0.111
-	$\sigma$	-	C <sub>13</sub> -C <sub>14</sub>	$\pi^*$	0.17309	37.81	0.13	0.106
LPN <sub>10</sub>	$\sigma$	0.81494	C <sub>12</sub> -O <sub>16</sub>	$\pi^*$	0.18382	27.67	0.26	0.108
LPO <sub>15</sub>	$\sigma$	0.98597	C <sub>13</sub> -C <sub>14</sub>	$\sigma^*$	0.01569	4.22	1.06	0.085
-	$\pi$	0.88385	C <sub>13</sub> -C <sub>14</sub>	$\pi^*$	0.17309	22.49	0.32	0.110
LPO <sub>16</sub>	$\sigma$	0.98828	N <sub>10</sub> -C <sub>12</sub>	$\sigma^*$	0.03861	0.94	1.04	0.040
-	$\pi$	-	N <sub>10</sub> -C <sub>12</sub>	$\sigma^*$	0.03861	11.50	0.62	0.107
-	$\pi$	-	C <sub>12</sub> -C <sub>14</sub>	$\sigma^*$	0.02821	8.07	0.69	0.095
LPO <sub>19</sub>	$\pi$	0.92775	C <sub>18</sub> -N <sub>20</sub>	$\sigma^*$	0.02662	8.34	0.79	0.105
LPN <sub>20</sub>	$\pi$	-	C <sub>18</sub> -O <sub>19</sub>	$\pi^*$	0.98887	28.99	0.23	0.104
LPO <sub>32</sub>	$\pi$	0.93175	C <sub>28</sub> -C <sub>31</sub>	$\sigma^*$	0.98606	7.71	0.67	0.093
LPO <sub>32</sub>	$\pi$	-	C <sub>31</sub> -O <sub>33</sub>	$\sigma^*$	0.99564	16.26	0.54	0.119
LPO <sub>33</sub>	$\sigma$	-	C <sub>31</sub> -O <sub>32</sub>	$\pi^*$	0.99259	21.43	0.30	0.106
LPO <sub>36</sub>	$\pi$	0.98819	C <sub>35</sub> -O <sub>37</sub>	$\sigma^*$	0.99554	16.30	0.54	0.119
LPO <sub>37</sub>	$\pi$	0.91664	C <sub>35</sub> -O <sub>36</sub>	$\pi^*$	0.13399	21.44	0.31	0.105

**Table 6**

Polarizability values of CPCHODQ6C with halogen substitutions

	$\mu$ debye	$\alpha \times 10^{-23}$ esu	$\beta \times 10^{-30}$ esu	$\gamma \times 10^{-37}$ esu	MR = $1.333\pi\alpha N$
CPCHODQ6C	3.7723	3.835	15.827	-37.219	96.680
7F	2.4881	3.852	14.266	-40.117	97.113
8F	3.3922	3.835	18.475	-38.524	96.684
9F	4.0094	3.844	15.433	-38.203	96.911
7Cl	2.2885	4.090	14.706	-43.982	96.684
8Cl	3.3286	4.014	19.209	-41.111	103.113
9Cl	4.2570	4.019	16.340	-40.007	101.323
7Br	2.6165	4.200	14.325	-46.681	105.886
8Br	3.4016	4.103	18.702	-42.842	103.441
9Br	4.3456	4.097	14.845	-41.671	103.289

**Table 7.**

Values of solubility parameters  $\delta$  [MPa<sup>1/2</sup>] for studied molecules and selected frequently used excipients

Molecules	$\delta$ [MPa <sup>1/2</sup> ]
CPCHODQ6C	27.411
PVP	18.515
Maltose	28.564
Sorbitol	32.425

**Table 8**

PASS prediction for the activity spectrum of CPCHODQ6C compound. Pa represents probability to be active and Pi represents probability to be inactive.

Pa	Pi	Activity
0.858	0.015	Ubiquinol-cytochrome-c reductase inhibitor
0.855	0.012	Methylenetetrahydrofolate reductase (NADPH) inhibitor
0.823	0.020	Testosterone 17beta-dehydrogenase (NADP+) inhibitor
0.777	0.017	Taurine dehydrogenase inhibitor
0.731	0.004	5 Hydroxytryptamine release inhibitor
0.732	0.014	Glutathione thiolesterase inhibitor
0.709	0.016	NADPH-cytochrome-c2 reductase inhibitor
0.705	0.015	2-Dehydropantoate 2-reductase inhibitor
0.700	0.012	Pterin deaminase inhibitor
0.690	0.005	N-methylhydantoinase (ATP-hydrolysing) inhibitor
0.711	0.026	Glutamate-5-semialdehyde dehydrogenase inhibitor
0.688	0.007	Aminobutyraldehyde dehydrogenase inhibitor
0.687	0.012	Kidney function stimulant
0.668	0.016	Fatty-acyl-CoA synthase inhibitor
0.673	0.029	Fusarinine-C ornithinesterase inhibitor
0.656	0.015	L-glutamate oxidase inhibitor
0.656	0.023	UDP-N-acetylglucosamine 4-epimerase inhibitor
0.641	0.008	Erythropoiesis stimulant
0.653	0.021	2-Hydroxyquinoline 8-monooxygenase inhibitor
0.639	0.007	Histamine release inhibitor
0.659	0.028	Ribulose-phosphate 3-epimerase inhibitor
0.646	0.017	Insulysin inhibitor
0.653	0.029	Dehydro-L-gulonate decarboxylase inhibitor

**Table 9**

The binding affinity values of different poses of the compound predicted by Autodock Vina.

Mode	Affinity (kcal/mol)	Distance from best mode (Å)	
-	-	RMSD l.b.	RMSD u.b.
1	-9.1	00.000	00.000
2	-8.7	23.021	25.648
3	-8.6	21.625	24.204
4	-8.5	04.709	06.627
5	-8.5	22.282	24.626
6	-8.2	15.464	16.890
7	-8.0	17.626	19.186
8	-8.0	02.659	10.111
9	-7.8	22.017	24.050



**Table 10.**

Drug-Likeness properties of the CPCHODQ6C compound

CPCHODQ6C	
MW	368.3 g/mol
nRot	5
HBA	7
HBD	5
TPSA	156.79Å <sup>2</sup>
MlogP	0.96